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Abbreviations
ACA Anterior cerebral artery
ApoE Apolipoprotein E
BCA Brachiocephalic artery
BMT Bone marrow transplantation
CAD Coronary artery disease
CBF Cerebral blood flow
CCA Common carotid artery
CCR2 CC chemokine receptor 2
CLC Contralateral cortex
CLS Contralateral striatum
CXCL1 Chemokine (C X C motif) ligand 1
DT Diphtheria toxin
ELISA Enzyme linked immunosorbent assay
FACS Fluorescence activated cell sorting
FoxP3 Forkhead box P3
GAPDH Glyceraldehyde 3 phosphate dehydrogenase
GWAS Genome wide association study
H&E Hematoxylin and eosin
HAT Histone acetyltransferase
HDAC9 Histone deacetylase 9
HDRP Histone deacetylase related protein
HPRT Hypoxanthine guanine phosphoribosyl transferase
IC Infarct core
IFN Interferon
IL 10 Interleukin 10
LDL Low density lipoprotein
LDLR Low density lipoprotein receptor
LVS Large vessel stroke
MCA Middle cerebral artery
MCAo Middle cerebral artery occlusion
MCP 1 Monocyte chemoattractant protein 1
MEF2 Myocyte enhancer factor 2
oxLDL Oxidized LDL
PBMCs Peripheral blood mononuclear cells
Abbreviations
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PComA Posterior communicating artery
PFA Paraformaldehyde
PIR Peri infarct region
Rag 1 Recombination activating gene 1
ROI Region of interest
SCA Subclavian artery
SCID Severe combined immunodeficiency
SMC Smooth muscle cell
SNP Single nucleotide polymorphism
TGF Transforming growth factor
TOAST Trial of organization 10172 in acute stroke treatment
tPA Tissue plasminogen activator
Tregs Regulatory T cells
TUNEL Terminal deoxynucleotidyl transferase dUTP nick end labeling
VCAM 1 Vascular cell adhesion molecule 1
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1 Summary
In a genome wide association study for ischemic stroke, the so far strongest risk locus for
large vessel stroke was identified in the histone deacetylase 9 (HDAC9) gene region at
chromosome 7p21.1. HDAC9 mRNA levels were found to be increased in peripheral blood
mononuclear cells of healthy risk allele carriers of the lead SNP rs2107595, suggesting that
increased HDAC9 expression enhances the risk for large vessel stroke. These findings make
HDAC9 a promising candidate gene for atherosclerosis and stroke. In this thesis, we
investigated the consequences of HDAC9 deficiency on atherosclerosis and ischemic stroke
outcome.
ApoE deficient mice (ApoE / ) were used as a model for atherosclerosis. We analyzed the
effects of HDAC9 deficiency on atherosclerotic plaque size in ApoE deficient mice at
different ages and on different diets. Compared to HDAC9+/+ApoE / mice, HDAC9 / ApoE /
mice showed reduced atherosclerotic lesion sizes and less advanced lesions, when they
were fed a chow diet. However, no difference was observed in more advanced
atherosclerosis after a high cholesterol Western type diet, indicating a protective role of
HDAC9 deficiency in early atherogenesis. Immunological analyses by flow cytometry
showed a shift in monocyte populations from classical, inflammatory monocytes to more
resident monocytes in HDAC9 / ApoE / mice. Moreover, T cell analysis revealed a reduction
in effector memory T cells in chow fed HDAC9 / ApoE / mice, indicating decreased activation
and migration of T cells. These findings suggest that both innate and adaptive immunity
play an important role in the atheroprotective effect of HDAC9 deficiency.
For ischemic stroke outcome, we used a transient focal ischemia model which is based on
the occlusion of the middle cerebral artery (MCAo) for one hour, using a filament inserted
via the internal carotid artery. In contrast to the protective effect of HDAC9 deficiency in
atherosclerosis, HDAC9 / mice showed increased infarct volumes and more severe
neurological deficits 24 hours as well as 7 days after MCAo. TUNEL staining revealed
increased cell death in peri ischemic areas of HDAC9 / mice, indicating a protective role of
HDAC9 in the brain parenchyma.
Our results suggest a pro atherogenic but neuroprotective role of HDAC9. Specific
pharmacological inhibition of HDAC9 might be a promising strategy to prevent
atherosclerosis, but not to improve ischemic stroke outcome. Thus, potential effects of
HDAC9 inhibitors on the brain have to be considered.
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2 Introduction
2.1 Stroke
Epidemiology
Stroke is the second most common cause of death worldwide (Lozano et al., 2012). In the
United States, every 40 seconds someone has a stroke and every 4 minutes someone dies
of a stroke (Mozaffarian et al., 2015). Incidence for stroke varies between countries,
ranging worldwide from 60 to 504 cases per 100,000 people per year (Feigin et al., 2014). In
2010, stroke was at the third rank of major causes for reduced disability adjusted life years
(DALYs, the sum of years of life lost and years lived with disability) (Murray et al., 2012). The
lifetime risk for stroke is 1 out of 5 women and 1 out of 6 men (Seshadri and Wolf, 2007). In
2010, total European costs for stroke were 64.1 billion Euros (Olesen et al., 2012). Stroke is
an increasing health problem worldwide because of demographic changes confronting us
with an aging population.
Stroke is characterized by neurological deficits which are based on an acute focal injury of
the central nervous system due to a vascular cause (Sacco et al., 2013) and can be
subdivided into ischemic (80%) and hemorrhagic stroke (20%). While hemorrhagic stroke
results from a rupture of a vessel leading to extravasation of blood, ischemic stroke is
caused by the narrowing or occlusion of a brain supplying artery, for example due to an
embolus or a local thrombus.
Ischemic stroke subtypes
Based on the mechanism causing the vessel occlusion, ischemic stroke can be classified
according to the pathophysiological Trial of Organization 10172 in Acute Stroke Treatment
(TOAST) criteria as cardioembolic stroke, large vessel stroke (LVS), small vessel occlusion
(lacunes), stroke of other determined etiology or stroke of undetermined etiology (Adams
et al., 1993) (Figure 1). Cardioembolic stroke is induced by an embolus arising from the
heart, for example as a result of atrial fibrillation. In patients with LVS one of the major
brain arteries or branch cortical arteries is occluded or has a significant stenosis (> 50%) by
atherosclerotic plaques. Stroke due to small vessel disease (microangiopathy of the small
cerebral vessels including small arteries, arterioles, capillaries and venules) is characterized
Introduction
5
by subcortical or brainstem infarcts (diameter less than 1.5 cm), collectively called lacunar
infarcts.
Figure 1. Etiology of ischemic stroke.
Frequencies are taken from the Stroke Data Bank of the German Stroke Foundation (Grau et al.,
2001).
Therapy of ischemic stroke
In acute ischemic stroke, the most effective treatment after exclusion of a hemorrhagic
cause by CT (computed tomography) scan is thrombolysis by recombinant tissue
plasminogen activator (tPA) to recanalize the vessel and reperfuse the brain (The National
Institute of Neurological Disorders and Stroke rt PA Stroke Study Group, 1995). The time
window of only 4.5 hours after stroke onset is essential for this therapy (Hacke et al., 2008).
Recent studies showed that tPA in combination with stent retriever thrombectomy
improves functional outcome in comparison to tPA medication alone, which is a
breakthrough in acute stroke management (Jovin et al., 2015; Saver et al., 2015). As
secondary prevention of recurrent stroke, patients receive antiplatelet agents such as
aspirin and dipyridamole, statins for treating hypercholesterolemia and anticoagulants in
case of atrial fibrillation. When stenosis of the symptomatic carotid artery is at least 70%,
carotid endarterectomy is performed (Donnan et al., 2008). Specific treatment options for
stroke are still limited, since disease mechanisms are poorly understood.
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Genetics of ischemic stroke
Ischemic stroke is a heterogeneous multifactorial disease. Modifiable risk factors
(hypertension, smoking, diabetes, atrial fibrillation and obesity) and acquired risk factors
(age, gender and race ethnicity) can explain part of the stroke risk, but from twin and family
studies we know that also genetic factors play a substantial role (Goldstein et al., 2006).
Twin studies showed that the concordance rate for stroke is fivefold higher in monozygotic
twins than in dizygotic twins (Brass et al., 1992). The heritability of ischemic stroke is
estimated at 37.9%, but varies for the different subtypes: 40.3% for LVS, 32.6% for
cardioembolism, and 16.1% for small vessel disease (Bevan et al., 2012). These differences
emphasize the importance of stroke subtyping for identifying genetic associations.
To discover novel genetic components influencing ischemic stroke risk, two approaches are
commonly used: candidate gene association studies (Hirschhorn et al., 2002) and genome
wide association studies (GWAS) (Wang et al., 2005). Both approaches make use of
common (frequency >1%) genomic variants usually affecting a single nucleotide (single
nucleotide polymorphisms, SNPs) to identify disease risk genes. The majority of these
variants has no consequences on protein sequences or expression. However, some of them
are located in coding regions and can cause amino acid exchanges altering protein
structure, others are situated in regulatory regions and might influence gene expression. In
both cases, this might result in an increased disease risk. In the candidate gene approach
the frequencies of variants in a known gene are compared between stroke patients and
controls, but in the past only very few hits have been successfully replicated, probably due
to small sample sizes, poor stroke subtype classification and study design (Dichgans and
Markus, 2005). Therefore, current research focuses more and more on GWAS in order to
identify risk loci in complex diseases. Here a large number of variants from the whole
genome are compared between cases and controls. Some of them might have an impact for
example on stroke risk by affecting conventional risk factors such as hypertension (Marteau
et al., 2005) or by modulating diseases including atherosclerosis (Lusis et al., 2004;
Stylianou et al., 2012). But they could also influence infarct size or stroke outcome, making
GWAS a highly promising approach to identify novel risk factors.
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2.2 A new risk locus for large vessel stroke the 7p21.1 region
As part of the International Stroke Genetics Consortium and the Wellcome Trust Case
Control Consortium 2, we recently contributed to a GWAS conducted on ischemic stroke
(Bellenguez et al., 2012). 495,851 SNPs were analyzed in 3,548 stroke cases and 5,972
controls, all of European ancestry. Stroke cases were classified according to the TOAST
classification into LVS, cardioembolism, and small vessel disease. Previous risk loci for
cardioembolic stroke (PITX2 and ZFHX3) (Gretarsdottir et al., 2008; Gudbjartsson et al.,
2009; Lemmens et al., 2010) and one locus for LVS (9p21.3) (Gschwendtner et al., 2009)
could be replicated. Additionally, a novel locus for LVS at the 7p21.1 region the strongest
risk locus for this stroke subtype to date was identified and replicated in an independent
cohort (Bellenguez et al., 2012). The METASTROKE collaboration could confirm this novel
risk locus in a combined data set from available GWAS with 12,389 stroke cases and 62,004
controls from 15 different populations, all of European ancestry (Traylor et al., 2012). In the
METASTROKE study, the rs2107595 SNP was the most significant variant with a P value of
2.03×10 12. The population attributable risk was estimated to be 4.5%, the odds ratio was
1.39 (95% CI: 1.27 1.53) and the risk allele frequency was 16% (Traylor et al., 2012). The
7p21.1 locus encompasses the 3’ end of the histone deacetylase 9 (HDAC9) gene and the
intergenic region between HDAC9 and its neighboring genes, TWIST1 and FERD3L (Figure 2).
Introduction
8
Figure 2. Plot of association signals in the 7p21.1 region.
rs2107595, the lead SNP from the METASTROKE data set (Traylor et al., 2012), and all other
associated signals are located at the 3’ end of the HDAC9 gene and in the intergenic region between
HDAC9 and the neighboring genes, TWIST1 and FERD3L. Figure adapted from Azghandi et al., 2015.
The same locus was found by the CARDIOGRAM Consortium to be associated with coronary
artery disease (CAD) and myocardial infarction (Deloukas et al., 2013). This is in line with
the strong overlap of genetic susceptibility between ischemic stroke, especially LVS, and
CAD (Dichgans et al., 2014). Moreover, several variants within the 7p21.1 region show
association with both conditions, indicating that they act through a shared mechanism.
Since LVS and CAD are both primarily caused by atherosclerosis, the 7p21.1 region likely
represents a risk locus for this disease.
2.3 Atherosclerosis
Development of atherosclerotic plaques
Atherosclerosis is the major contributor to cardiovascular disease including stroke and
myocardial infarction. It is a progressive inflammatory disease of the arterial wall
characterized by accumulation of intra and extracellular lipids and fibrous material in the
inner lining of arteries, the tunica intima. The word “atherosclerosis” is derived from the
Greek words “athera” (gruel) and “sklerosis” (hardening). Until the 1970s atherosclerosis
has been considered as a disease of lipid deposition since there is a strong correlation
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between hyperlipidemia and atherosclerosis (Ross and Harker, 1976). But in the past
decades the involvement of both innate and adaptive immunity became clear.
Atherosclerosis develops in several steps (Figure 3). The anatomy of a normal arterial wall is
shown in Figure 3A. The initiating step in atherosclerosis is endothelial activation due to
endothelial injury, hyperlipidemia or pro inflammatory mediators. Low density lipoprotein
(LDL) infiltrating the tunica intima can be modified by oxidation and induces an
inflammatory response of the endothelium (Skalen et al., 2002; Hansson, 2005). This
subendothelial retention of lipoproteins by the extracellular matrix leads to the expression
of endothelial adhesion molecules (Nakashima et al., 1998) and the recruitment of
leukocytes to the tunica intima (Figure 3B). Monocytes infiltrate the intima, differentiate
into tissue macrophages and take up lipoproteins, including oxidized LDL. These
macrophages become foam cells, a histological term derived from their lipid laden, foamy
appearance. Early atherosclerotic lesions, called “fatty streaks”, consist of subendothelial
accumulation of foam cells (Figure 3C) and can already be found in the aorta of children in
the first decade of life (Lusis, 2000). These lesions have no clinical relevance, but they can
progress to advanced lesions which form mainly at branch points of arteries because of
blood flow turbulences (Lusis, 2000). Advanced lesions are characterized by a fibrous cap
formed by smooth muscle cells and extracellular matrix, a lipid rich necrotic core and
surrounding leukocytes of the innate and adaptive immunity (Figure 3D and 3E).
The necrotic core consists of dying foam cells which release their lipid content and thereby
contribute to the excess of extracellular lipids in the lesion. Smooth muscle cells migrate
from the tunica media into the intimal lesion, secreting extracellular matrix components
and thereby increasing the lesion size. Initially, the atherosclerotic plaque grows into the
direction of the tunica adventitia, but after reaching a critical point it grows toward the
blood vessel lumen resulting in a decrease in vessel diameter. A plaque can grow gradually
until it reduces the blood flow in a vessel, leading to a stenosis. But the most important
complication of atherosclerosis is plaque rupture, which exposes procoagulant material
often leading to a local thrombus or an embolus occluding a distal artery. The thickness of
the fibrous cap, grade of inflammation, and necrotic core size are critical parameters for
rupture prone, so called vulnerable plaques (Finn et al., 2010).
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Figure 3. Stages in the development of atherosclerosis.
A, Scheme of a normal, healthy artery consisting of three layers, the tunica intima with the
endothelium, the tunica media with vascular smooth muscle cells (SMCs), and the tunica adventitia
with connective tissue. B, The initial step of atherogenesis is the expression of endothelial adhesion
molecules after endothelial activation, the subsequent adhesion and migration of monocytes into
the tunica intima and their differentiation into macrophages. C, Macrophages phagocytose
lipoprotein particles, become foam cells and form so called fatty streaks. SMCs migrate out of the
tunica media into the tunica intima. D, SMCs produce extracellular matrix molecules such as collagen
and start to form a fibrous cap. E, Apoptosis of foam cells and SMCs leads to the formation of a
necrotic core with extracellular lipids. An advanced atheroma develops with a fibrous cap covering
the necrotic, lipid core.
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Mouse models of atherosclerosis
Animal models of atherosclerosis have been developed in a variety of species including
rabbits, pigs and non human primates. However, the most important and most commonly
used laboratory model is the mouse (Getz and Reardon, 2012). Under normal conditions
wild type mice do not develop atherosclerotic lesions, but deletion of the apolipoprotein E
(ApoE) gene leads to spontaneous atherosclerotic plaque formation (Plump et al., 1992;
Nakashima et al., 1994). Atherogenesis in this model is accelerated by feeding a high
cholesterol diet, for example a Western type diet (Figure 4). Another mouse model for
atherosclerosis is based on low density lipoprotein receptor (LDLR) deficiency. These mice
have to be fed a high cholesterol diet to develop atherosclerotic plaques. Although the sites
of lesion formation in both mouse models (aortic root, aortic arch and brachiocephalic
artery) are different from humans (coronary, carotid and periphery arteries) (Getz and
Reardon, 2012), plaque types and phases of their development are highly comparable
(Figure 4). However, the process of atherothrombosis due to plaque rupture cannot be
studied in mouse models since vulnerable plaques do not develop. Nevertheless, the results
of studies in mouse models have strongly advanced our understanding of atherosclerotic
processes. Both the ApoE / and the LDLR / model are widely used to test therapeutic
options for atherosclerosis or, after breeding them to other transgenic or knockout mice, to
study the role of different factors, e.g. components of the immune system in atherogenesis.
In addition, bone marrow transplantation into ApoE / or LDLR / mice can be performed to
investigate the contribution of bone marrow derived cells. Collectively, advantages of
possible genetic manipulation as well as short breeding times and relatively low costs for
husbandry in comparison to other mammalian species make the mouse the most
frequently used and favored model in atherosclerosis research.
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Figure 4. Timeline of atherosclerotic lesion development in ApoE deficient mice.
Feeding a high cholesterol Western type diet accelerates atherogenesis in comparison to a standard
chow diet (adapted from Nakashima et al., 1994).
Role of the immune system in atherosclerosis
The immune system plays an important role in the initiation, the progression, and the
rupture of atherosclerotic lesions. The perception of atherosclerosis as a chronic
inflammatory disease has replaced the earlier concept which focused entirely on lipid
metabolism (Weber et al., 2008). A wide range of immune cell mediated cascades promote
atherosclerosis. For instance, vascular cell adhesion molecule 1 (VCAM 1) has a major role
in the initiation of atherosclerosis as an early endothelial leukocyte adhesion molecule
(Cybulsky and Gimbrone, 1991; Cybulsky et al., 2001). VCAM 1 selectively binds monocytes
and lymphocytes, the predominant leukocyte subtypes in atherosclerotic plaques, and its
expression increases in response to hypercholesterolemia at lesion prone sites of the aorta
(Nakashima et al., 1998). Diphtheria toxin (DT) mediated depletion of monocytes in a
CD11b DT receptor transgenic mouse model led to a significant reduction of early plaque
formation, whereas DT application had no effect on size and composition of established
plaques, suggesting that monocytes play an important role in early atherogenesis
(Stoneman et al., 2007). Different subsets of monocytes can be distinguished according to
their expressed chemokine receptors: the short lived inflammatory (CX3CR1low CCR2+ Ly6Chi)
subset and the resident subset (CX3CR1hi CCR2 Ly6Clow) which represent patrolling
monocytes on healthy endothelium and react immediately to an infection by inducing an
early immune response (Auffray et al., 2007; Weber et al., 2008). It has been shown that
hypercholesterolemia increases numbers of blood circulating Ly6Chi monocytes, which
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infiltrate lesions of atherosclerotic mice (Swirski et al., 2007). Chemokines like the
monocyte chemoattractant protein 1 (MCP 1/CCL2) play an important role in the
recruitment and migration of monocytes into the tunica intima. Absence of MCP 1 or its
receptor, CC chemokine receptor 2 (CCR2) leads to decreased atherosclerotic lesion
formation in experimental atherosclerosis models (Boring et al., 1998; Gu et al., 1998).
Monocytes in the tunica intima differentiate to macrophages in response to macrophage
colony stimulating factor (M CSF), produced by endothelial and smooth muscle cells
(Rajavashisth et al., 1990).
Besides monocytes/macrophages, T cells, dendritic cells, mast cells, B cells, and neutrophils
are present in atherosclerotic plaques. Macrophages and CD4+ T helper cells as well as
CD8+ cytotoxic T cells are the predominant immune cell types of human atherosclerotic
plaques (Jonasson et al., 1986; Stemme et al., 1992). Initially, it was thought that T cells are
not playing a major role in atherosclerosis based on studies showing that ApoE / mice with
a strongly compromised immune system because of inactivation of the recombination
activating gene 1 (Rag 1) have unchanged atherosclerotic lesion sizes when fed a Western
type diet. But when a normal chow diet was used, they showed a 42% reduction in lesion
size (Dansky et al., 1997). Similarly, immunodeficient ApoE / /scid/scid mice show a 73%
reduction in lesion size under chow diet (Zhou et al., 2000). An adoptive transfer of
CD4+ T cells into ApoE / /scid/scid mice aggravates atherosclerosis to almost the same
degree as in immunocompetent ApoE / mice. Type 1 T helper (TH1) cells are the most
prevalent T cell subtype in human atherosclerotic lesions (Frostegard et al., 1999) and the
pro inflammatory cytokine interferon (IFN ), which is secreted by TH1 cells, appears to be
proatherogenic (Whitman et al., 2000; Zhou et al., 2000). Analysis of the T cell antigen
receptors expressed in atherosclerotic lesions showed a restricted pattern, suggesting
oligoclonal T cell expansion and specific antigen processes in atherosclerosis (Paulsson et
al., 2000). Isolated T cells from human atherosclerotic plaques react to oxLDL, making this
metabolite a prime candidate antigen for atherosclerosis specific inflammatory processes
(Stemme et al., 1995).
But some immune cell types and cytokines from the adaptive immunity show also
atheroprotective properties like regulatory T cells (Tregs) and their cytokines interleukin 10
(IL 10) and transforming growth factor (TGF ). Tregs are T cells with immunosuppressive
functions and essential for maintaining self tolerance and the prevention of autoimmunity.
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They can be generated in the thymus as naturally occurring Tregs or induced in the
periphery from naïve CD4+ T cells (Ait Oufella et al., 2014). Tregs are characterized by the
expression of the forkhead/winged helix transcription factor FoxP3. It was shown that
inhibition or deficiency of the Treg cytokines IL 10 and TGF aggravates atherosclerosis
(Mallat et al., 1999; Mallat et al., 2001). Furthermore, depletion of Tregs by neutralizing
antibody treatment or by diphtheria toxin increases atherosclerosis significantly (Ait Oufella
et al., 2006; Klingenberg et al., 2013), making Tregs an interesting target for therapeutic
intervention.
In the last years, also the role of neutrophils has been intensely investigated in
atherosclerosis. It could be shown that neutrophils are present in early and advanced
atherosclerotic lesions in experimental mouse models (van Leeuwen et al., 2008; Drechsler
et al., 2010; Rotzius et al., 2010) as well as in human atherosclerotic plaques (Ionita et al.,
2010). Plasma levels of neutrophil granule proteins such as myeloperoxidase (MPO) are
candidates for biomarkers, for example to predict coronary artery disease risk (Zhang et al.,
2001).
In summary, the immune system is a major driver of atherosclerosis development and
represents an important target for therapeutic intervention. However, the molecular
players involved in the inflammatory processes contributing to atherosclerosis are
incompletely described. The GWAS approach is highly suited to identify novel treatment
targets for atherosclerosis.
2.4 Candidate genes at the 7p21.1 locus
The 7p21.1 locus is the so far strongest risk locus for large vessel stroke. However, all
identified SNPs are localized in intronic or intergenic regions making an explanation for the
underlying molecular mechanisms difficult. The 7p21.1 region contains three potential
candidate genes, HDAC9, TWIST1 and FERD3L (see Figure 2).
TWIST1 and FERD3L code for transcription factors of the helix loop helix family involved in
cell differentiation processes during embryogenesis. The factor Nato3 encoded by the
FERD3L gene is dynamically expressed in the floor plate of the neural tube during both
midbrain (Ono et al., 2010) and spinal cord development (Mansour et al., 2014). TWIST1
plays an important role in the differentiation of mesenchymal stem cells in chondrocytes,
adipocytes and osteoblasts (Miraoui and Marie, 2010). Additionally, pathological conditions
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of TWIST1 are known. Mutations in humans cause the autosomal dominant
Saethre Chotzen syndrome (SCS), also called acrocephalosyndactyly III (ACS III), which is
characterized by facial dysmorphism, limb abnormalities, and craniosynostosis (El Ghouzzi
et al., 1999).
HDAC9 belongs to the evolutionary conserved family of histone deacetylases (HDACs)
which together with the histone acetyltransferases (HATs) regulate the acetylation of
histone and non histone proteins and play important roles in several physiological and
pathological conditions (Haberland et al., 2009). HDAC9 is mainly expressed in the heart,
brain, and muscle. HDACs are also known to be involved in inflammation and immunity
(Shakespear et al., 2011), which play an important role in atherosclerosis.
To investigate which of the three genes might be responsible for the association of the
7p21.1 locus with LVS, my colleague Caroline Prell Schicker quantified their mRNA levels in
peripheral blood mononuclear cells (PBMCs) of healthy blood donors. HDAC9, but not
TWIST1 or FERD3L, was found to be elevated in risk allele carriers of the lead SNP
rs2107595 (see Figure 5 and manuscript 1 of this thesis) (Azghandi et al., 2015). This made
HDAC9 the most promising candidate gene in the 7p21.1 region and indicated that it has an
atherogenic role.
Figure 5. Expression levels of HDAC9, but not of TWIST1 and FERD3L, are increased in peripheral
blood mononuclear cells of healthy homozygous and heterozygous risk allele (A) carriers.
Relative mRNA expression levels of HDAC9, TWIST1 and FERD3L in healthy subjects in respect to the
rs2107595 genotype. *P<0.05, **P<0.01, n.s. not significant. Figure from Azghandi et al., 2015.
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2.5 Histone deacetylases
Histones are the most important components of chromatin and thus major regulators of
gene transcription. Within their N terminal domains they contain a number of positively
charged basic amino acids which interact with the negatively charged DNA backbone to
promote chromatin condensation. Such compacted DNA is inaccessible for binding factors
and thus transcriptionally silent. Posttranslational modification of histones such as
acetylation and methylation has been known since the 1960s to control chromatin
structure (Allfrey et al., 1964). For example acetylation of the amino group of lysine
residues within histone tails relaxes chromatin structure by neutralizing the positive charge.
This results in increased accessibility of genomic DNA for transcription regulating factors
(Shahbazian and Grunstein, 2007). Two families of enzymes, the histone deacetylases
(HDACs) and histone acetyltransferases (HATs), regulate the acetylation and deacetylation
of histones (Figure 6), but also of non histone proteins including transcription factors and
heat shock proteins. One of their main functions is the regulation of chromatin remodeling
and gene expression (Shahbazian and Grunstein, 2007). HDACs and HATs are regulating
diverse developmental processes, but are also involved in physiological and pathological
processes in the adult organism (Haberland et al., 2009).
Classification of HDACs
The 18 members of the HDAC family can be grouped into four classes (I, II, III and IV), based
on sequence homology and domain organization. Class I, II and IV are the classical HDACs
which use Zn2+ as a cofactor whereas class III HDACs, the sirtuins 1 7, are NAD+ dependent
(Shakespear et al., 2011). Class I consists of HDAC1, HDAC2, HDAC3 and HDAC8 which
localize to the nucleus and are expressed ubiquitously. HDAC9 belongs, together with
HDAC4, HDAC5 and HDAC7, to class IIa HDACs which have an N terminal binding domain
mediating the interaction with transcriptional repressors and activators such as myocyte
enhancer factor 2 (MEF2) (Haberland et al., 2009). Class IIa HDACs can shuttle between the
nucleus and cytoplasm, a process regulated by phosphorylation through kinases such as
calcium/calmodulin dependent protein kinase (CaMK) and binding of 14 3 3 proteins
(McKinsey et al., 2000). In contrast to class I HDACs, class IIa HDACs have a more restricted
tissue expression pattern, for example HDAC5 and HDAC9 show a strong expression in the
brain, the heart, and the muscle (Zhang et al., 2002; Chang et al., 2004). Furthermore, it
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was shown that class IIa HDACs have a lower deacetylase activity in comparison to
class I HDACs (Lahm et al., 2007). However, class IIa HDACs can recruit class I HDACs,
thereby acquiring increased enzymatic capacity (Fischle et al., 2002). The class IIb HDACs
encompass HDAC6 and HDAC10. HDAC6 is a cytoplasmic HDAC with two deacetylase
domains which interacts with cytoskeletal proteins, e.g. tubulin (Matsuyama et al., 2002).
Class IV HDACs consist of HDAC11 about which little is known.
Figure 6. Histone deacetylases and histone acetyltransferases.
Histone acetylation is controlled by two families of enzymes, the histone deacetylases and the
histone acetyltransferases. Positively charged amino groups of lysine residues within histone tails
interact with the negatively charged DNA backbone to promote compaction of the chromatin
structure. Acetylation of these groups disrupts interactions and results in chromatin relaxation which
is required for transcription to occur. Deacetylation reverses this process resulting in transcriptional
repression.
HDAC functions
The roles of HDACs were studied in several disease models including cardiovascular
diseases such as cardiac hypertrophy and neointima formation as well as neurological
diseases such as Huntington`s disease and stroke. Cardiac hypertrophy is a response of
cardiomyocytes to stimuli like hypertension or valvular dysfunction. Deficiency of the
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class IIa HDACs 5 and 9 was shown to promote cardiac hypertrophy (Zhang et al., 2002;
Chang et al., 2004). In contrast, pan HDAC inhibitors and class I selective HDAC inhibitors
can prevent and even reverse cardiac hypertrophy suggesting that class I HDACs oppose
class II function in the regulation of cardiac hypertrophy (Kook et al., 2003; Kee et al., 2006).
The role of HDACs was also studied in vascular smooth muscle cells and endothelial cells
which are both important cell types for atherosclerosis and neointima formation. HDAC
inhibition prevents mitogen induced proliferation of smooth muscle cells by inducing G1 cell
cycle arrest (Findeisen et al., 2011). Furthermore, different HDAC inhibitors attenuated
neointima formation in vivo (Findeisen et al., 2011; Kee et al., 2011), making HDACs an
interesting target for vascular remodeling and atherosclerosis. HDAC3 has prosurvival
functions in endothelial cells and knockdown of HDAC3 in endothelial cells of aortic
isografts leads to severe atherosclerosis and vessel rupture, demonstrating that HDAC3 is
critical for endothelial cell function (Zampetaki et al., 2010). HDAC4 was shown to be
associated with carotid intima media thickness, indicating an involvement of HDAC4 in
atherosclerosis (Lanktree et al., 2009).
Besides beneficial effects in cancer and cardiovascular diseases, HDAC inhibitors show
neuroprotective properties in neurological and neurodegenerative diseases (Kazantsev and
Thompson, 2008), like Huntington`s disease (Ferrante et al., 2003; Kazantsev and
Thompson, 2008) and stroke (Faraco et al., 2006; Kim et al., 2007). Several HDAC inhibitors
led to reduced infarct volumes and ameliorated functional outcome in experimental animal
stroke models (Kim et al., 2007; Langley et al., 2008). Proposed mechanisms include
suppression of inflammation (Kim et al., 2007) and increased expression of neuroprotective
factors like heat shock protein 70 (Hsp70), B cell lymphoma 2 (Bcl 2), gelsolin and
phosphorylated Akt (Faraco et al., 2006; Kim et al., 2007; Yildirim et al., 2008).
Inhibition of HDACs is a promising approach to control pathological processes. Several
HDAC inhibitors have been developed and already tested in preclinical models and clinical
trial settings. Known inhibitors can be subdivided into four classes, the hydroxamic acids,
short chain fatty acids, cyclic tetrapeptides, and benzamides. Most of the currently
available HDAC inhibitors inhibit multiple members of the HDAC family and are thus mostly
non selective. HDAC inhibitors were originally found as anticancer therapeutics by inducing
apoptosis, differentiation, but also by reducing proliferation and angiogenesis (Falkenberg
and Johnstone, 2014). Some HDAC inhibitors have already been approved for therapeutic
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treatment, e.g. suberoylanilide hydroxamic acid (SAHA, vorinostat) for cutaneous T cell
lymphoma (Marks and Breslow, 2007) or the short chain fatty acid valproic acid (VPA) for
epilepsy (Marson et al., 2007).
Thus, there is substantial evidence from the literature about the role of HDACs in
cardiovascular and neurological conditions. In combination with our mRNA expression data
from PBMCs (Figure 5) this motivated us to focus on HDAC9 as the most promising risk gene
within the 7p12.1 locus.
2.6 HDAC9
HDAC9 is mainly expressed in the brain, heart and skeletal muscle. Global HDAC9 deficient
mice were already generated in 2002 by the group of Eric N. Olsen to study the role of
HDAC9 in suppressing cardiac hypertrophy (Zhang et al., 2002). By homologous
recombination with a targeting vector, exon 4 and most of exon 5 of HDAC9, which encode
the MEF2 binding domain, were deleted. Homozygous HDAC9 / mice are viable, but they
develop cardiac hypertrophy with advanced age or in response to stress signals such as
pressure overload or activated calcineurin (Zhang et al., 2002). This pathological condition
is caused by derepression of MEF2, a transcription factor expressed in myocytes and a key
regulator of cardiac hypertrophy. Interestingly, the MEF2 interacting transcriptional
repressor (MITR), a HDAC9 splice variant, can also repress MEF2 activity despite lacking the
deacetylase domain, indicating that the catalytic activity is not essential for regulating
cardiac hypertrophy (Zhang et al., 2002).
Several studies suggest an important role of HDACs on Treg function. Administration of
HDAC inhibitors increases the production and the function of FoxP3 positive Tregs in the
human and in the murine system (Tao et al., 2007; Akimova et al., 2010). Moreover, HDAC9
seems to regulate FoxP3 mediated suppression of Tregs. Tao et al. could show that the
number of FoxP3 positive T cells was increased in lymphoid tissues of HDAC9 knockout
mice. HDAC9 deficient Tregs were found to be more suppressive than wild type Tregs and
showed increased FoxP3 acetylation (Tao et al., 2007). In line with this, HDAC9 deficient
mice were protected in several autoimmune disease models like colitis (de Zoeten et al.,
2010; Yan et al., 2011).
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In addition to LVS and CAD, the HDAC9 gene region (7p21.1) has also been associated with
carotid intima media thickness and with carotid plaque presence (Markus et al., 2013).
Furthermore, HDAC9 was expressed in human vascular smooth muscle end endothelial cells
and HDAC9 expression was increased in human carotid, aortic, and femoral atherosclerotic
plaques (Markus et al., 2013). This represented additional evidence for a role of HDAC9 in
atherogenesis.
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3 Project design
3.1 Aims of the thesis
The 7p21.1 locus is the strongest risk locus for LVS to date (Bellenguez et al., 2012) and has
also been associated with CAD (Deloukas et al., 2013) and carotid intima media thickness
(Markus et al., 2013). This provided strong evidence for a role of this locus in
atherosclerosis. On the basis of mRNA studies in human PBMCs and the described role of
HDACs in cardiovascular and neurological diseases, HDAC9 was selected as the most likely
disease causing gene within the risk locus. Due to the significant increase in HDAC9 mRNA
levels in risk allele carriers of the lead SNP, we hypothesized that HDAC9 deficiency could
have beneficial effects. This was in line with published findings demonstrating
neuroprotective effects of HDAC inhibitors. The goal of this PhD project was to study the
consequences of HDAC9 deficiency in a mouse knockout model. First, a potential role in the
cardiovascular system was investigated using an established mouse model for
atherosclerosis. Second, HDAC9 deficient mice were subjected to transient middle cerebral
artery occlusion (MCAo) to analyze effects on ischemic stroke.
In particular, this thesis had the following objectives:
A. To determine the influence of HDAC9 deficiency on atherosclerotic plaque formation.
HDAC9 deficient mice were crossed with ApoE knockout mice, a widely used animal
model for atherosclerosis. The parameters atherosclerotic plaque size, immune cell
infiltration, and plaque stages were analyzed. The results are presented in manuscripts
1 and 2.
B. To determine the influence of HDAC9 deficiency on immune cell homeostasis.
Flow cytometric analysis was used in manuscript 2 to study the distribution of different
immune cell types in HDAC9 deficient mice.
C. To examine the role of HDAC9 deficiency in ischemic stroke.
In manuscript 3, HDAC9 deficient mice were subjected to transient MCAo. Infarct size,
neurological status and other parameters of stroke outcome were analyzed.
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3.2 Experimental strategy
All animal studies were done on littermates, using HDAC9 heterozygous mice as breeders.
Two different mouse lines were used. On the one hand, the HDAC9 deficient mice without
ApoE deficiency were investigated (HDAC9 / mice and their wild type littermates, HDAC9+/+
mice) and on the other hand, the HDAC9 deficient mice which were crossed to
atherosclerosis prone ApoE deficient mice (HDAC9 / ApoE / mice and their wild type
littermates HDAC9+/+ApoE / mice).
Objective A and B: To determine the influence of HDAC9 deficiency on atherosclerotic plaque
formation and immune cell homeostasis
Atherosclerotic plaque size was analyzed in the aortic root and the aortic arch in chow and
Western type diet fed HDAC9 / ApoE / mice and their wild type littermates. First, I had to
establish all techniques including dissection, histological analyses, and flow cytometry in
our institute. When the mice reached the right age, they were anesthetized, blood was
taken for the immunological analyses and the vessels were perfused with the vasodilator
nitroprusside to achieve maximal vasodilation. The aortic arch with the main branching
arteries (right and left subclavian and common carotid arteries) (Figure 7A) was dissected
and analyzed histologically (Figure 7B). Additionally, the heart was taken out and cut at the
level of the aortic valves (Figure 7C). Besides plaque size, plaque stages, and immune cell
infiltration were analyzed. The distribution of different immune cell types was studied by
flow cytometric analysis (Figure 7D) of the blood and the spleen. Besides HDAC9 ApoE
double knockout mice, HDAC9 deficient mice without ApoE deficiency were examined in
the immunological analyses to be able to discriminate the HDAC9 effect without disease
from the effect in combination with atherosclerosis.
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Figure 7. Work flow for atherosclerotic plaque (Objective A) and FACS analysis (Objective B) in
HDAC9 ApoE double knockout mice.
After anesthetizing the mouse, blood is taken out by cardiac puncture and vessels are perfused
with the vasodilator nitroprusside. The spleen is removed, followed by perfusion with
1% paraformaldehyde (PFA) for fixation and dissection of the aortic arch and the heart. In A, the
main branching arteries of the aortic arch are shown. In B, and C, examples of an H&E stained aortic
arch section and an Oil Red O stained aortic valve section are depicted. In D, examples of
fluorescence activated cell sorting (FACS) analysis of the blood and the spleen are presented.
Objective C: To examine the role of HDAC9 deficiency in ischemic stroke.
For this objective, HDAC9 deficient mice without ApoE deficiency were used to study the
effect of HDAC9 in stroke without the involvement of atherosclerosis. The transient middle
cerebral artery occlusion model was used which is based on the occlusion of the middle
cerebral artery (MCA) for one hour using a silicone coated monofilament inserted via the
internal carotid artery (Figure 8). Infarct volume, neurological status, edema formation, and
other parameters of stroke outcome were analyzed in HDAC9 deficient mice and their wild
type littermates.
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Figure 8. The middle cerebral artery occlusion (MCAo) model (Objective C).
The left common and external carotid arteries are ligated and a silicone coated monofilament is
inserted via the internal carotid artery. After one hour of ischemia, reperfusion is initiated by
removing the filament. Anterior cerebral artery (ACA); basilar artery (BA); common carotid artery
(CCA); external carotid artery (ECA); internal carotid artery (ICA); middle cerebral artery (MCA);
posterior cerebral artery (PCA); posterior communicating artery (PComA); superior cerebellar
artery (SCA).
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Abstract
Background and Purpose: Recent genome wide association studies identified the HDAC9
gene region as a major risk locus for large vessel stroke and coronary artery disease (CAD).
However, the mechanisms linking variants at this locus to vascular risk are poorly
understood. In this study, we investigated the candidacy and directionality of HDAC9 in
atherosclerosis and analyzed associations between risk alleles at 7p21.1 and plaque
characteristics.
Methods: Allele dependent expression of HDAC9 was analyzed in human peripheral blood
mononuclear cells (PBMCs) of healthy donors. Effects of HDAC9 deficiency on
atherosclerotic plaques were investigated in 18 and 28 week old ApoE / mice by histology
and immunohistochemistry. We further performed detailed plaque phenotyping and
genotyping of rs2107595, the lead SNP in METASTROKE, in carotid endarterectomy samples
of 1,858 subjects from the Athero Express Study.
Results: Gene expression studies in PBMCs revealed increased mRNA levels of HDAC9 but
not of neighboring genes (TWIST1/FERD3L) in risk allele carriers of rs2107595. Compared to
HDAC9+/+ApoE / mice, HDAC9 / ApoE / mice exhibited markedly reduced lesion sizes
throughout atherosclerotic aortas and significantly less advanced lesions. The proportion of
Mac3 positive macrophages was higher in plaques from HDAC9 / ApoE / mice, but this was
largely due to a lower proportion of advanced lesions. Analysis of human atherosclerotic
plaques revealed no association between rs2107595 and specific plaque characteristics.
Conclusions: Our results suggest that HDAC9 represents the disease relevant gene at the
stroke and CAD risk locus on 7p21.1 and that risk alleles in this region mediate their effects
through elevated HDAC9 expression. Targeted inhibition of HDAC9 might be a viable
strategy to prevent atherosclerosis.
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Introduction
Stroke and coronary artery disease (CAD) are among the most common causes of
premature death and loss of disability adjusted life years worldwide.1,2 About a quarter of
all strokes are classified as large vessel stroke (LVS) most of which are attributed to
atherosclerosis. LVS shares many risk factors with CAD and both conditions have a strong
heritable component.3,4
In a genome wide association study (GWAS) we recently identified the histone
deacetylase 9 (HDAC9) gene region on chromosome 7p21.1 as the strongest risk locus for
LVS to date.5,6 Variants at this locus were subsequently shown to be also associated with
CAD7 and common carotid intima media thickness (IMT)8 suggesting that the effects of the
7p21.1 region are mediated through atherosclerosis.
rs2107595, the lead SNP in METASTROKE,6 is located 3’ to the HDAC9 gene. The next two
genes, TWIST1 and FERD3L, reside 100 kb downstream to rs2107595 whereas other genes
are more than 500 kb away. Histone deacetylases (HDACs) mediate the acetylation of
histones and non histone proteins together with histone acetylases.9 The balance between
acetylation and deacetylation plays a critical role in gene expression mechanisms during
embryonic development and disease states in later life.10 HDAC9 has been implicated in
immune mediated mechanisms and is expressed in various cell types relevant to
atherosclerosis including inflammatory, vascular endothelial and smooth muscle cells.8,11,12
Hence, HDAC9 represents a strong candidate gene for atherosclerosis. However, there are
no expression data supporting the candidacy of HDAC9 over other genes at 7p21.1. Also,
the relationship between risk variants in this region and plaque morphology remains to be
determined. We thus investigated samples from healthy subjects and patients undergoing
carotid endarterectomy.13 We further tested the hypothesis that deficiency of HDAC9
attenuates atherosclerosis in mice.
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Materials and Methods
Allele carrier status and mRNA expression
DNA and RNA were isolated from peripheral blood mononuclear cells (PBMCs) of healthy
donors (43 male, 34 female, age 65.3±20.8 [mean±SD] years). Carrier status at rs2107595
was determined by direct sequencing. RNA was isolated using PAXgene Blood RNA Kit
(PreAnalytiX GmbH) according to the manufacturer`s protocol. For each sample, 800 ng of
DNase treated RNA were converted into cDNA (Omniscript RT Kit, Qiagen) using Oligo
dT(15) primer. For quantitative real time PCR cDNAs were diluted with water 1:9 and
analyzed using TaqMan Gene Expression Assays (ABI Bioscience) for human HDAC9,
TWIST1, FERD3L and RPLP0. Measurements were performed in triplicates. Results for target
genes were normalized to the reference gene RPLP0 and to a calibrator sample. All subjects
provided written informed consent.
Atherosclerotic plaque analysis in mice
All animal protocols were approved by the government of Upper Bavaria. HDAC9 / mice
from E. Olson14 were provided by Laurent Schaeffer (Université Lyon) and were crossed
with ApoE deficient mice (The Jackson Laboratory) to generate HDAC9 / ApoE / mice. Mice
had ad libitum access to food and water and were housed under a 12 h light dark cycle. All
experiments were done on male littermates fed a standard chow diet to sensitively capture
the effect of HDAC9 on spontaneous rather than aggravated and accelerated
atherosclerosis induced by western type diet. Animals were sacrificed at age 18 or
28 weeks (n = 8 13 for each genotype and time point) by an overdose of ketamine and
xylazin. Blood was obtained by cardiac puncture from the right ventricle and plasma was
used for cholesterol measurements using a colorimetric assay (Cayman Chemical
Company). The arterial tree was perfused through the left ventricle with 6 ml phosphate
buffered saline (PBS, containing sodium nitroprusside (1 mg/ml, Sigma Aldrich)) to achieve
vasodilation and 10 ml 1% paraformaldehyde (PFA) for tissue fixation. The aortic arch and
its main branch points were removed and fixed for 24 h in a 1% PFA solution.
To evaluate atherosclerotic lesion size, a total of 8 cryosections (8 m) extending cranially
through the aortic valves at 104 m intervals were cut. Lesion area per cross section and
relative area of lesions were quantified. Relative lesion area was calculated for each section
as R% = (100 × L/A), where L is lesion area and A is area inside the external elastic lamina.
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The relative lesion area was expressed as the mean of four consecutive sections (104 μm
416 μm) per mouse. We further measured plaque sizes of the aortic arch of 28 week old
mice. The aortic arch was embedded in paraffin and cut into consecutive 4 μm sections.
Four sections at 20 μm intervals were chosen for plaque analysis. Sections were stained
with hematoxylin and eosin (H&E) and lesion areas of the total aorta as well as individual
lesions at the main branch points and the curvature were measured by AxioVision Software
(Zeiss, Germany). The number of plaques per arch was counted. Atherosclerotic lesions
were classified as initial or advanced using the Virmani classification.15 The number of
nuclei and the acellular core area per plaque in the brachiocephalic artery were quantified.
Immunohistochemistry was performed on paraffin sections of the aortic arch (n = 8 13 for
each phenotype). A Mac3 monoclonal antibody (1:100 dilution, M3/84, BD Bioscience) to
detect macrophages and an isotype matched control antibody were used. Antibodies were
titrated to optimal performance and applied to PFA fixed paraffin sections of the aortic
arch followed by detection using an ABC peroxidase kit and DAB substrate (both from
Vector Laboratories). The stainings were quantified by ImageJ Software and the number of
Mac3 positive cells per lesion was divided by the total number of cells per lesion, as
determined by number of nuclei per lesion.
All experiments and data analysis were performed under blinded conditions for the
genotype.
rs2107595 and human atherosclerotic plaques
Human carotid atherosclerotic plaques (N=1,858) were obtained from the Athero Express
Study, an ongoing, longitudinal, multi center study collecting carotid atherosclerotic
plaques from patients with significant (>70%) stenosis who undergo carotid
endarterectomy.13,16 The medical ethics committee of the participating centers approved
the study and written informed consent was obtained from all patients.
Immunohistochemical plaque phenotyping was performed as described elsewhere.13,16 In
brief, carotid plaques were divided into segments of 5 mm thickness. The culprit lesion was
defined and used for immunohistochemical staining. Calcification (hematoxylin & eosin,
H&E) and collagen content (picrosirius red) were semi quantitatively defined as no or minor
vs. moderate/heavy staining as previously described.13,16 Atheroma size was defined as less
than or more than 10% fat content (H&E and picrosirius red). We quantitatively scored
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macrophages (CD68) and smooth muscle cells ( actin) as percentage plaque area. We also
determined the presence of intraplaque hemorrhage (H&E) and counted the number of
vessel per 3 4 hotspots (CD34).
Genotyping was done in two batches using Affymetrix arrays. rs2107595 was imputed using
phased data from HapMap 2 (release 22, b36) as a reference. Quality control (QC) was
performed according to standard procedures. Detailed description of genotyping, quality
control and imputation is provided in the online only Data Supplement.
Statistical analysis
For the human mRNA expression data and the murine plaque analysis, GraphPad Prism 5
(GraphPad Software) and SigmaPlot 12.5 (Systat Software Inc.) were used for statistical
analysis. Groupwise comparisons (n>2) were performed using a nonparametric Kruskal
Wallis test followed by a Mann Whitney test. Pairwise comparisons were performed using a
Mann Whitney test. Differences were considered statistically significant at P<0.05. Data are
expressed as mean±SEM.
For statistical analysis of the Athero Express data quantitative histological phenotypes were
normalized through natural log (LN) transformation; outliers deviating more than ±3 SD
from the LN transformed mean were removed. Genetic analyses were corrected for age,
sex, 10 principal components, year of surgery and a dummy variable representing the two
genotyping batches, assuming an additive genetic model. Linear and logistic regression
models were used for quantitative and binary phenotypes, respectively. IBM SPSS Statistics
version 20 (release 20.0.0, IBM Corp., Armonk, NY, USA) was used for statistical analyses of
baseline characteristics. PLINK v1.7 and Golden Helix SNP & Variation Suite v8.1.5 (Golden
Helix, Inc., Bozeman, MT, USA) were used for genetic analyses. Our power to detect an
association between rs2107595 and individual plaque phenotypes at a significance level of
0.05 [0.005] with a sample size of 1,400, an effect size of 0.182 and a minor allele frequency
of 20% was >90% [>75%] for quantitative phenotypes. For binary phenotypes our power to
detect an OR of 1.20 (corresponding to an effect size of 0.182) was between 20% [4%] (for
collagen) and 54% [23%] (for intraplaque hemorrhage). To account for testing multiple
phenotypes the level of statistical significance was set at 0.005.
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Results
rs2107595 risk allele carriers show increased HDAC9 mRNA expression in PBMCs
rs2107595, the lead SNP in METASTROKE,6 is situated in the intergenic region between
HDAC9 and TWIST1/FERD3L and co localizes with both Deoxyribonuclease I (DNase I)
hypersensitivity clusters and histone modification hotspots (UCSC Genome Browser,17
genome build hg18, Figure 1A), suggesting a possible involvement of this variant in gene
regulation.
Figure 1. HDAC9 mRNA levels are significantly elevated in risk allele carriers of the lead SNP
(rs2107595) found to be associated with large vessel stroke. A, Regional association plot of the
HDAC9 gene region showing association signals around rs2107595 for LVS in the METASTROKE
dataset.6 Top, SNPs are colored based on their correlation with rs2107595, which has the smallest
P value in the region. Bottom, DNase I hypersensitivity clusters and histone modification hotspots
(H3K4Me1, H3K27Ac). B, Relative mRNA expression of HDAC9 in human PBMCs for different
genotypes of rs2107595. HDAC9 mRNA levels are significantly elevated in homozygous and
heterozygous carriers of the risk allele (A) with a gene dosage effect (GG n=51, GA n=22, AA n=4).
Results represent mean±SEM. *P<0.05, **P<0.01 (Kruskal Wallis test P=0.003, followed by Mann
Whitney test).
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We thus measured mRNA expression levels of HDAC9, TWIST1 and FERD3L in PBMCs from
healthy donors. HDAC9 mRNA levels were significantly increased in homozygous and
heterozygous carriers of the risk allele (rs2107595A) with a gene dosage effect (Figure 1B).
In contrast, mRNA levels of the adjacent genes TWIST1 and FERD3L did not correlate with
allele carrier status at rs2107595 (Figure I in the online only Data Supplement), suggesting
that variants at this locus regulate HDAC9 expression and that the effects of this locus on
stroke risk might be mediated through elevated HDAC9 expression.
HDAC9 deficiency reduces atherosclerotic lesion size in mice
To test the hypothesis that HDAC9 deficiency attenuates atherogenesis and to refine its
influence on plaque composition, we crossed HDAC9 / mice with ApoE / mice and fed them
a normal chow diet. HDAC9 / ApoE / mice showed a significant reduction of atherosclerotic
lesion size at both 18 weeks and 28 weeks of age in aortic valve sections (Figure 2A and 2B)
as well as in aortic arch sections (Figure 2C and 2D).
A significant reduction in plaque area was also found in the brachiocephalic artery and
aortic curvature (Figure IIA in the online only Data Supplement). The number of plaques in
the aortic arch was significantly reduced (Figure IIB in the online only Data Supplement).
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Figure 2. HDAC9 deficiency reduces atherosclerotic plaque size in ApoE deficient mice.
A, Representative images showing Oil Red O and hematoxylin stained cryosections from the
proximal aorta of HDAC9+/+ApoE / and HDAC9 / ApoE / mice at 18 and 28 weeks of age. Scale bars:
250 μm. B, Absolute plaque areas at different distances from the aortic valves of 18 week old mice
(top) and relative plaque area (in relation to the area inside of the external elastic lamina) (bottom).
C, Representative images showing dissected aortic arches of 28 week old mice. D, Total plaque area
in the aortic arch of 28 week old mice. Values represent mean plaque area for each mouse; n = 8 13
for each genotype and time point; *P<0.05; **P<0.01 vs. wildtype (Mann Whitney test).
Next, we categorized atherosclerotic lesion stage using the Virmani classification.15 We
distinguished intimal xanthomas consisting mainly of foam cells from advanced atheromas
characterized by fibrous cap and acellular areas. In brachiocephalic artery plaques (Figure
3A and 3B) only 2 out of 8 HDAC9 / ApoE / mice showed acellular areas compared to 12 out
of 13 HDAC9+/+ApoE / (P<0.01) (Figure 3C). The reduction in acellular cores corresponded to
the increased number of nuclei per lesion area in HDAC9 / ApoE / mice (Figure 3D).
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Figure 3. HDAC9 deficiency affects composition of atherosclerotic plaques in the brachiocephalic
artery (BCA) of 28 week old mice. A, Overview of aortic arch. Orange rectangle indicates region of
interest for plaque analysis in the BCA. B, Representative images of H&E stained plaques are shown.
C, Acellular core per lesion area in the BCA. D, Nuclei per lesion area in the BCA. n = 8 13 for each
genotype; scale bars: 100 m; *P<0.05; **P<0.01 vs. wildtype (Mann Whitney test); BCA
brachiocephalic artery, CCA common carotid artery, SCA subclavian artery, Curv. aortic curvature.
Analysis of the entire aorta likewise revealed a lower proportion of advanced lesions in
HDAC9 deficient mice (HDAC9+/+ApoE / : 43±7%; HDAC9 / ApoE / : 12±6%; [mean±SEM];
Figure 4A). In addition, immunostaining for Mac3 showed a higher proportion of
macrophages in plaques from HDAC9 / ApoE / mice (Figure 4B and 4C). However, after
exclusion of advanced lesions no difference of Mac3 infiltration was observed. Plasma
cholesterol levels measured at 18 and 28 weeks did not differ between HDAC9 / ApoE / and
HDAC9+/+ApoE / mice (Figure IIC in the online only Data Supplement).
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Figure 4. HDAC9 deficiency affects stages and composition of atherosclerotic plaques in the aorta of
28 week old mice. A, Classification of aortic arch lesions according to their stage of atherosclerosis.
Initial plaques (intimal xanthomas and pathological intimal thickenings); advanced plaques (fibrous
cap atheromas). B, Immunostaining for Mac3 and quantification of Mac3 positive cells in all plaques
in the total aorta and in initial plaques only (following exclusion of advanced atheromas). n = 8 13 for
each genotype; scale bars: 100 m; *P<0.05; **P<0.01 vs. wildtype (Mann Whitney test).
rs2107595 has no discernable effect on plaque morphology in humans
To explore potential associations between risk alleles at HDAC9 and specific advanced
plaque characteristics we genotyped 1,858 subjects with available detailed plaque
phenotyping from Athero Express. 1,439 subjects passed quality control. Their
demographic and clinical characteristics are presented in Table I in the online only Data
Supplement. There was no significant association between rs2107595 and specific plaque
characteristics in the overall sample (Table 1) or when analysis was restricted to patients
with asymptomatic plaques, symptomatic plaques or stroke (Table II in the online only Data
Supplement).
Table 1. Association of rs2107595 with plaque phenotypes in the Athero Express Study (N=1,439).
MAF OR ß 95% CI SEM P Phenotype N
0.800 1.129 NA 0.93 1.38 NA 0.215 calcification 705/700
0.800 0.877 NA 0.69 1.12 NA 0.284 collagen 1129/277
0.800 1.164 NA 0.94 1.44 NA 0.162 atheromasize 1018/389
0.800 1.211 NA 0.99 1.48 NA 0.058 intraplaquehemorrhage 849/557
0.800 NA 0.120 NA 0.089 0.176 macrophages 1403
0.800 NA 0.071 NA 0.064 0.261 smoothmuscle cells 1375
0.797 NA 0.036 NA 0.037 0.329 vessel density 1216
MAF: major allele frequency; odds ratios (OR) and effect sizes (ß) are relative to the major allele (G)
on genome build 36; P values are two sided. Phenotype: calcification and collagen are coded as no
or minor vs. moderate heavy staining, atheroma size is coded as <10% vs. >10% fat content,
intraplaque hemorrhage as no vs. yes, macrophages and smooth muscle cells are natural log (LN)
transformed percentages of plaques, and vessel density is the LN transformed average intraplaque
vessel density per 3 4 hotspots. N is the number of patients analyzed for the respective plaque
phenotype. SEM: standard error of the mean; NA: not applicable.
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Discussion
This study provides converging evidence that HDAC9 represents the disease relevant gene
at the stroke and CAD risk locus on 7p21.1 and that risk alleles at this locus mediate their
effects through increased HDAC9 expression.
Our finding of elevated HDAC9 mRNA expression in risk allele carriers of rs2107595, the
lead SNP in METASTROKE, is consistent with recent data from the ENCODE project showing
that the majority of disease associated variants are located in regulatory regions and
control genes within a distance of ±500 kb. rs2107595 resides inside a DNase I
hypersensitivity cluster and histone modification hotspot. In fact, rs2107595A is predicted
to disrupt a consensus sequence for an E2F3 binding site (TRANSFAC database,18 data not
shown), a transcription factor forming a repressor complex with Rb proteins, thus raising
the possibility that this variant is implicated in gene regulation. However, the exact
mechanism by which genetic variation at this locus regulates HDAC9 expression remains to
be determined. TWIST1 and FERD3L, the only other genes nearby, exhibited no allele
dependent mRNA expression and are thus less likely to be implicated in locus specific
effects. However, because our expression analyses were restricted to PBMCs, we cannot
exclude regulatory effects in other cell types.
Complementing our expression data, we found deficiency of HDAC9 to attenuate
atherogenesis in ApoE / mice. The reduction of atherosclerotic lesion size reaching up to
45% in 28 week old animals, was present throughout all segments of the aortic arch (aortic
valves, curvature, branching arteries) and already significant in 18 week old animals.
Staging of lesions further revealed that HDAC9 / ApoE / mice had significantly less advanced
lesions compared to HDAC9+/+ApoE / mice. Together, these findings demonstrate a strong
effect of HDAC9 expression on atherogenesis. The higher proportion of Mac3 positive
macrophages in plaques from HDAC9 / ApoE / mice likely reflects the lower proportion of
acellular areas that are typical for advanced lesions as there was no difference of Mac3
infiltration when we restricted our analyses to intimal xanthomas. Hence, we found no
obvious influence of HDAC9 deficiency on plaque morphology.
In accordance with our findings in mice, no significant association between rs2107595 and
specific plaque characteristics was found in human carotid plaques from the Athero Express
Study. Importantly, our power to detect an association with macrophage count, smooth
muscle cell count, and vessel density was over 75%. Hence, we are confident that we would
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have captured any prominent effect on these plaque phenotypes. However, our power to
detect associations with binary plaque phenotypes was limited. Thus, we cannot exclude
allele specific effects on collagen content, atheroma size, calcification, and intraplaque
hemorrhage. Interestingly, a recent meta analysis of population based cohorts revealed an
association of rs2107595 with carotid IMT measured by ultrasound.8 Taken together, these
data suggest that HDAC9 expression promotes early atherogenesis rather than accelerating
progression to vulnerable plaques. However, we cannot exclude skewing of macrophage
polarization from M1 to M2 phenotype as previously reported.19
The precise mechanisms by which elevated HDAC9 expression promotes atherogenesis and
vascular risk remain to be determined. A recent study found that targeted depletion of
HDAC9 in bone marrow cells attenuates atherogenesis in LDLr / mice.19 HDAC9 was further
shown to repress cholesterol efflux in macrophages. However, whether the changes in
macrophages give rise to atherosclerotic lesion formation remains speculative. Given the
widespread expression of HDAC9 in multiple cell types there are several mechanisms by
which elevated HDAC9 expression could promote atherosclerosis. For example, HDAC9 has
been shown to inhibit FOXP3 expression and the function of regulatory T cells,20 which
protect against atherosclerosis.21,22
Our findings imply that targeting HDAC9 may be a viable strategy to prevent atherosclerosis
progression. Broad spectrum HDAC inhibitors have multiple off target effects and
exacerbate atherosclerosis.23 Selective inhibitors of class IIa HDACs have recently been
developed but not yet sufficiently tested in vivo.24 Given the pleiotropic role of class IIa
HDACs developing inhibitors with selectivity for HDAC9 seems the most promising approach
to specifically target atherosclerotic lesion formation.
In conclusion, this study provides mechanistic insights how genetic variation in the HDAC9
gene region, a major risk locus for LVS and CAD, promotes atherosclerosis. Moreover, our
findings suggest that selective pharmacological inhibition of HDAC9 may be an effective
strategy to prevent atherosclerosis and its clinical manifestations.
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Supplemental Methods
Human carotid plaque studies
Genotyping
We performed two genome wide association (GWA) experiments in 1,858 consecutive
patients from Athero Express Study. DNA was extracted from whole blood or carotid
plaques following standardized protocols. The first experiment was performed in the
Athero Express Genomics Study 1 (AEGS1; n=836 patients recruited between 2002 and
2007) and was carried out by AROS Applied Biotechnology (Denmark) under study number
A318 using the Affymetrix Genome Wide Human SNP Array 5.0 (SNP5) chip (Affymetrix Inc.,
Santa Clara, CA, USA). The second experiment was performed in the Athero Express
Genomics Study 2 (AEGS2; n=1,022 patients recruited between 2002 and 2013). These
samples were genotyped at the Genomic Analysis Center, Helmholtz Center Munich
(Germany) using the Affymetrix Axiom GW CEU 1 Array (AxM).
Genotyping quality control and imputation
Quality control (QC) was performed according to standard procedures. Genotype calling
was conducted using the standard settings of Affymetrix Genotyping Console 4.0 Software
(GCOS4) and the proper algorithm for each chip (BRLMM P for SNP5 and Axiom GT1 for
AxM, respectively). Subsequent QC included the following steps: We first excluded samples
with low average genotype calling and gender discrepancies (compared to clinical data)
based on GCOS4 metrics. Next, data were filtered on 1) individual (sample) call rate > 97%,
2) SNP call rate > 97%, 3) minor allele frequencies > 3%, 4) average heterozygosity rate ± 3.0
SD, 5) relatedness (pi hat > 0.20), 6) Hardy–Weinberg Equilibrium (HWE P value < 1.0x10 6),
and 7) population stratification (based on HapMap 2, release 22, b36) by excluding samples
deviating more than 6 standard deviations from the average in 5 iterations during principal
component analysis and by visual inspection. All subjects were of self reported European
ancestry, which was confirmed through PCA. After QC 657 and 869 samples from AEGS1
and AEGS2 respectively, were available for imputation. A total of 403,789 markers in AEGS1
and 535,983 in AEGS2 were included before imputation. Autosomal missing genotypes
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were imputed in both datasets using phased data from the HapMap 2 project1 (release 22,
b36) and BEAGLE2 v3.3.2 (31 October 2011).
Statistical analysis
For statistical analysis quantitative histological phenotypes were normalized through
natural log (LN) transformation; outliers deviating more than ±3 SD from the LN
transformed mean were removed. Genetic analyses were corrected for age, sex,
10 principal components, year of surgery and a dummy variable representing the two
genotyping batches, assuming an additive genetic model. Linear and logistic regression
models were used for quantitative and binary phenotypes, respectively. IBM SPSS Statistics
version 20 (release 20.0.0, IBM Corp., Armonk, NY, USA) was used for statistical analyses of
baseline characteristics. PLINK3 v1.7 and Golden Helix SNP & Variation Suite v8.1.5 (Golden
Helix, Inc., Bozeman, MT, USA) were used for genetic analyses. Our power to detect an
association between rs2107595 and individual plaque phenotypes at a significance level of
0.05 [0.005] with a sample size of 1,400, an effect size of 0.182 and a minor allele frequency
of 20% was >90% [>75%] for quantitative phenotypes. For binary phenotypes our power to
detect an OR of 1.20 (corresponding to an effect size of 0.182) was between 20% [4%] (for
collagen) and 54% [23%] (for intraplaque hemorrhage). To account for testing multiple
phenotypes the level of statistical significance was set at 0.005.
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Supplemental Tables
Table I. Demographic characteristics of the Athero Express Study.
Characteristic
Total sample, N 1,439
Age in years, mean (SD) 68.31 (9.31)
Sex, male, % 67.89
Mean arterial pressure (SD), mmHg 106.71 (15.86)
Total cholesterol (SD), mmol/l 4.72 (1.24)
Smoking, % 34.26
Diabetes mellitus, % 22.79
BMI (SD), kg/m2 26.29 (3.86)
Time since last cerebrovascular event, median (IQR), days 43.50 (18 92)
Index event, %
Asymptomatic 28.42
Symptomatic 70.95
Transient ischemic attack 44.34
Stroke 26.62
SD: standard deviation. IQR: interquartile range.
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Table II. Association of rs2107595 with plaque phenotypes in patient subgroups from the Athero
Express Study.
MAF OR 95% CI P Phenotype N
asymptomatic (N=409)
0.800 0.786 0.53 1.16 0.229 calcification 234/168
0.799 1.024 0.63 1.67 0.926 collagen 339/63
0.799 1.146 0.78 1.69 0.496 atheroma size (10%) 268/135
0.799 1.698 1.16 2.49 0.007 intraplaque hemorrhage 229/173
0.799 1.347 0.97 1.88 0.079 macrophages 399
0.801 0.868 0.70 1.07 0.188 smooth muscle cells 397
0.791 1.015 0.89 1.16 0.825 vessel density 354
symptomatic (N=1,021)
0.801 1.230 0.98 1.55 0.077 calcification 469/525
0.802 0.768 0.58 1.02 0.072 collagen 787/208
0.802 1.169 0.90 1.51 0.234 atheroma size (10%) 742/253
0.802 1.082 0.85 1.37 0.520 intraplaque hemorrhage 616/379
0.802 1.078 0.87 1.33 0.482 macrophages 995
0.801 0.947 0.81 1.10 0.487 smooth muscle cells 969
0.801 0.954 0.87 1.04 0.297 vessel density 858
stroke (N=383)
0.800 1.404 0.96 2.05 0.081 calcification 175/198
0.800 0.720 0.44 1.19 0.201 collagen 306/67
0.800 1.159 0.76 1.78 0.499 atheroma size (10%) 276/97
0.801 0.809 0.54 1.21 0.307 intraplaque hemorrhage 232/140
0.800 1.178 0.85 1.63 0.324 macrophages 374
0.802 1.048 0.83 1.32 0.693 smooth muscle cells 364
0.809 0.954 0.82 1.12 0.559 vessel density 317
MAF: major allele frequency; odds ratios (OR) are relative to the major allele (G) on genome build
36; P values are two sided. Phenotype: calcification and collagen are coded as no or minor vs.
moderate heavy staining, atheroma size is coded as <10% vs. >10% fat content, intraplaque
hemorrhage (IPH) as no vs. yes, macrophages and smooth muscle cells are natural log (LN)
transformed percentages of plaques, and vessel density is the LN transformed average intraplaque
vessel density per 3 4 hotspots. N is the number of patients analyzed for the respective plaque
phenotype. Asymptomatic: includes patients with significant stenosis (>50%) or ocular events
(including amaurosis fugax or retinal infarction) but no history of transient ischemic attack (TIA) or
stroke prior to carotid endarterectomy (CEA). Symptomatic: includes patients with a history of TIA or
stroke prior to CEA.
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Supplemental Figures
Figure I. Relative mRNA expression of HDAC9, TWIST1 and FERD3L in human PBMCs for different
genotypes of rs2107595. HDAC9 mRNA levels are significantly elevated in homozygous and
heterozygous carriers of the risk allele (A) with a gene dosage effect (GG n=51, GA n=22, AA n=4). For
TWIST1 (GG n=23, GA n=3, AA n=4) and FERD3L (GG n=23, GA n=3, AA n=1) no correlation with allele
carrier status was found. Results represent mean±SEM. *P<0.05, **P<0.01 (Kruskal Wallis test
followed by Mann Whitney test).
Figure II. A, Plaque area of the main branches and the curvature of the aorta in 28 week old mice.
B, Number of plaques per aortic arch. C, Plasma cholesterol in 18 and 28 week old male mice.
Results represent mean±SEM. n = 8 13 for each genotype and time point; *P<0.05; **P<0.01 vs.
wildtype (Mann Whitney test). BCA brachiocephalic artery, CCA common carotid artery,
SCA subclavian artery.
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Abstract
Cardiovascular diseases including stroke and ischemic heart disease belong to the most
common causes for mortality worldwide. Atherosclerosis is the underlying pathology for
these diseases. We could recently demonstrate that deficiency of histone deacetylase 9
(HDAC9), which was identified as a risk gene for large vessel stroke and coronary artery
disease, is atheroprotective in a mouse atherosclerosis model. The aim of the current study
was to investigate the effect of HDAC9 deficiency on atherosclerotic plaque size, immune
cell infiltration and immune cell distribution in mice using different dietary settings. We
could show that HDAC9 deficiency mainly affects early atherogenesis by delaying the
development of progressed atherosclerotic lesions. Using a Western type diet, where
lesions are in a more advanced stage, atherosclerotic lesion size was comparable between
HDAC9+/+ApoE / and HDAC9 / ApoE / mice. Flow cytometry analysis revealed a shift in
monocyte populations from classical, inflammatory monocytes to resident monocytes.
Furthermore, frequencies of monocytes/macrophages were reduced in the spleen of
HDAC9 deficient mice. In addition, T cell analysis revealed that chow fed HDAC9 / ApoE /
mice harbored significantly less effector memory T cells suggesting a decreased activation
and mobilization of T cells in HDAC9 deficient mice. These findings support our hypothesis
that both innate as well as adaptive immune responses play an important role in the
atheroprotective effect mediated by HDAC9 deficiency. Inhibition of HDAC9 seems to be a
promising therapeutic strategy for the prevention of atherosclerosis by modulating the
immune system.
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Introduction
Cardiovascular diseases including ischemic heart disease and stroke are major causes of
mortality worldwide.1 In recent genome wide association studies (GWAS), the histone
deacetylase 9 (HDAC9) gene region (7p21.1) was associated with large vessel stroke (LVS)2,3
and coronary artery disease (CAD).4 In the LVS study, the variant rs2107595, which locates
just downstream of the HDAC9 gene, was identified as the lead single nucleotide
polymorphism (SNP).3 HDAC9 belongs to the family of histone deacetylases (HDACs) which
consists of 18 members grouped in 4 classes.5 HDAC9 is a class IIa HDAC which in contrast
to class I HDACs are characterized by a tissue specific expression for HDAC9 mainly in the
heart, the brain and the immune system as well as by an N terminal domain mediating
interactions with transcription factors and transport proteins.5 7
Both LVS and CAD are mainly caused by atherosclerosis. We and others could recently
demonstrate that HDAC9 deficiency is atheroprotective using two different murine models
for atherosclerosis, ApoE / and LDLR / mice, respectively.8,9 While Cao et al. showed a
reduction of lesion sizes in HDAC9 / LDLR / mice fed with a Western type diet for 16 weeks,9
we made a similar observation in aortic valves and the aortic arch of HDAC9 / ApoE / mice
at two different time points (18 and 28 weeks of age) and under a normal chow diet.8
Furthermore, we observed that HDAC9 deficiency led to significantly more initial lesions
consequently showing increased macrophage infiltrations. These results are well in line
with the increased HDAC9 mRNA levels we measured in peripheral blood mononuclear cells
(PBMCs) of individuals carrying the rs2107595 risk allele.8
Atherosclerosis is a chronic inflammatory disease of the arterial wall. Both innate and
adaptive immunity play an important role in the initiation and progression of
atherosclerotic lesions.10 The predominant immune cells in atherosclerotic lesions are
macrophages and T cells. Recent studies have demonstrated an involvement of HDAC3 and
HDAC7 in macrophage polarization,11 13 as well as on T cell function, especially on
regulatory T cells.14,15 Cao et al. observed in HDAC9 deficient macrophages an increased
cholesterol efflux via the transporter proteins ABCA1 and ABCG1 and a polarization to the
more anti inflammatory M2 phenotype.9 A limitation of this study was the exclusive ex vivo
approach using bone marrow derived or peritoneal macrophages, stimulated and analyzed
in cell culture experiments, while the involvement of other immune cell types, such as T
cells, was neglected. The aim of the current study was to determine the effect of HDAC9
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deficiency on atherosclerotic plaque size and immune cell homeostasis after feeding
different diets.
Materials and Methods
Animals
All animal protocols were approved by the government of Upper Bavaria. HDAC9 / mice
from E. Olson7 were crossed with ApoE deficient mice (The Jackson Laboratory) to generate
HDAC9 / ApoE / mice. Mice had ad libitum access to food and water and were housed in a
specific pathogen free animal facility under a 12 h light dark cycle. All experiments were
performed on male littermates fed a standard chow diet for 18 or 28 weeks or a Western
type diet (21.2% fat, 0.2% cholesterol, and 33.2% sugar, ssniff) for 10 weeks, starting at
8 weeks of age. All experiments and data analysis were performed in a blinded fashion.
Following primers were used for HDAC9 genotyping:
5’ CAATTGACTATGCGGCTCT 3’ (wt forward),
5’ AGGCATGCTGGGGATGCGGTGGGC 3’ (ko forward),
5’ CCTTCCATATAAAACCAACTCC 3’ (reverse).
Bone Marrow Transplantation
Bone marrow cells were isolated from femur and tibia of 10 week old male HDAC9+/+ApoE /
mice or HDAC9 / ApoE / littermates and 1x107 bone marrow cells were injected
intravenously into lethally irradiated 6 week old male ApoE deficient mice. For two weeks
after the transfer, animals were treated with 1 g/L neomycin (Sigma Aldrich). After
additional two weeks of recovery, mice were fed a Western type diet for 10 weeks.
Tissue Harvesting
Mice were anesthetized using ketamine and xylazine. Blood was obtained by cardiac
puncture. The arterial tree was perfused through the left ventricle with phosphate buffered
saline (PBS), containing 1 mg/ml sodium nitroprusside (Sigma Aldrich) for vasodilation. The
spleen was removed prior to perfusion with 10 ml of 1% paraformaldehyde (PFA). The
aortic arch was dissected and fixed for 24 hours in 1% PFA solution. Half the spleen was
used to prepare a single cell suspension by mechanical disruption using a 40 μm nylon mesh
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(BD Falcon). For RNA expression analysis, the other half of the spleen was incubated in
RNAlater (QIAGEN) at 4°C overnight, shock frozen on dry ice the next day and stored at
80°C.
Plaque Size and Immunohistochemistry Analysis
Atherosclerotic plaque size at the aortic valves and in the aortic arch was quantified as
previously described.8 In the Western type diet fed mice, the acellular core area of the
plaque at the brachiocephalic artery (BCA) was measured on two aortic arch sections at a
distance of 40 μm by using the Axiovision software (Zeiss).
Immunohistochemistry was performed on heart cryosections at the level of the aortic
valves. We used a rat anti CD45 monoclonal antibody (1:200 dilution, 30 F11, BD
Pharmingen) to detect all infiltrated leukocytes and a Syrian hamster anti CD3 monoclonal
antibody (1:50 dilution, 500A2, BD Pharmingen) to detect T cells. Antibodies were titrated
to optimal performance and applied to acetone fixed cryosections of the aortic valves. Goat
secondary antibodies (Vector Laboratories) were used, followed by detection with an ABC
peroxidase kit and DAB substrate (both from Vector Laboratories). Stainings were
quantified using ImageJ Software. The CD45+ stained area and the number of CD3+ cells
inside the plaque or the lamina were divided by the lesion area.
Flow Cytometry Analysis
Flow cytometry analysis was performed on single cell suspensions of spleen or leukocytes
isolated from blood. Cells were stained in FACS buffer (1x PBS with 0.5% Bovine Serum
Albumin and 0.01% sodium azide) with the following fluorochrome labeled antibodies
against: CD45 (eFluor450, 30 F11, eBioscience), CD3 (FITC, 145 2C11, eBisocience), CD11b
(PerCp Cy5.5, M1/70, eBioscience), Ly6G (PE, 1A8, BD Pharmingen), Ly6C (APC, 1G7.G10,
Miltenyi), CD11c (PE Cy7, N418, eBioscience), CD4 (APC H7, GK1.5, BD Pharmingen), CD8
(eFluor450, 53 6.7, eBioscience), CD44 (APC, IM7, eBioscience), CD62L (PE Cy7, Mel 14,
eBioscience), and FoxP3 (PE, FJK 16a, eBioscience). Intracellular staining for FoxP3 was
performed using the anti mouse/rat FoxP3 Staining Set (eBioscience). Samples were
acquired on the FACSVerse (BD Biosciences) and data analysis was done using FlowJo
software (Tree Star).
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Real time PCR
Total RNA from spleens of 28 week old chow fed HDAC9 / ApoE / mice and their wild type
littermates was isolated by RNeasy Lipid Tissue Mini Kit (QIAGEN). cDNA was prepared from
1 μg RNA using the Omniscript RT Kit (QIAGEN) and diluted 1:5. For expression analysis of
interferon (IFN ), a reaction mix of 12 μl, including 2 μl cDNA, 200 nM IFN specific
primers (IFN forward: 5’ TCAAGTGGCATAGATGTGGAAGAA 3’; IFN reverse:
5’ TGGCTCTGCAGGATTTTCATG 3’) and Brilliant II SYBR Green QPCR Master Mix (Agilent
Technologies) was used. For CXCL1, CXCL2 and CXCL5, PrimeTime Mini qPCR Assays from
Integrated DNA Technologies were used. Real time PCR was performed on 384 well plates
using the LightCycler 480 (Roche Diagnostics). Glyceraldehyde 3 phosphate dehydrogenase
(GAPDH) was used as a house keeping gene. Measurements were performed in triplicates.
Data were analyzed based on the comparative threshold cycle method with the following
formula: Relative mRNA expression level = 2 Ct;
Ct = Ct, target Ct, calibrator; Ct = Ctarget gene Ct, GAPDH.
Average Ct values of wild type mice were used as calibrator.
ELISA
Splenocytes were cultured in the presence of anti CD3 (1 μg/ml, 500A2, BD Biosciences) or
anti CD3 plus anti CD28 (0.5 μg/ml, 37.51, eBioscience). After 48 hours of stimulation, cell
culture supernatants were collected and frozen at 20°C. Cytokine levels were measured by
matching antibody pairs for IFN (BD Pharmingen), IL 17 (eBioscience) and IL 10 (R&D).
Statistical analysis
GraphPad Prism 6 (GraphPad Software) and SigmaPlot 12.5 (Systat Software Inc.) were used
for statistical analysis. Pairwise comparisons were performed using the Mann Whitney test.
Differences were considered statistically significant at P<0.05. Data are expressed as mean
± SEM.
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Results and Discussion
Deficiency of HDAC9 has mainly an effect on early atherogenesis
To test the effect of HDAC9 deficiency on atherosclerosis at various time points using
different dietary settings, several groups of HDAC9 / ApoE / mice and their wild type
littermates were analyzed (Figure 1). Recently, we showed the influence of HDAC9
deficiency on atherosclerotic plaque size in ApoE deficient mice fed a normal chow diet.8 At
both 18 and 28 weeks of age, HDAC9 / ApoE / animals showed a significant reduction of
atherosclerotic lesion size in the aortic valves as well as in the aortic arch. In addition, we
observed that HDAC9 deficiency led to significantly less advanced lesions, and a
pronounced infiltration of macrophages. However, after exclusion of advanced atheromas,
we no longer observed any differences in the numbers of infiltrating macrophages into
initial lesions.8 In the current study, we analyzed infiltration of leukocytes (CD45+ cells) as
well as T cells (CD3+ cells) in aortic valve sections of 28 week old HDAC9 / ApoE / mice.
There were no differences, neither in the overall leukocyte infiltration (Supplementary
Figure S1A) nor in the number of T cells that migrated into the lamina or the plaque
(Supplementary Figure S1B). In addition to 18 and 28 week old animals fed a normal chow
diet, we also added a third group of Western type diet fed mice and a fourth group of bone
marrow transplanted mice to our analysis (Figure 1).
Figure 1. Study design. Four groups of mice were analyzed. The first two groups, 18 and 28 week
old HDAC9 / ApoE / mice and their wild type littermates were fed a normal chow diet. The third
group of mice was fed a high cholesterol Western type diet for 10 weeks, starting at an age of
8 weeks. The fourth group consisted of ApoE / mice which received bone marrow from HDAC9 /
ApoE / or from HDAC9+/+ApoE / donors after irradiation. After two weeks of antibiotics and two
additional weeks of recovery, the mice were fed a Western type diet for 10 weeks.
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To test the hypothesis whether immune cells are responsible for the atheroprotective
effect seen in HDAC9 deficient mice, we transplanted bone marrow from HDAC9 / ApoE /
mice or wild type littermates to lethally irradiated ApoE / mice and after four weeks of
recovery, mice were fed a Western type diet for 10 weeks. No differences in atherosclerotic
plaque size were observed in Western type diet fed mice or in bone marrow transplanted
animals, neither on the level of the aortic valves (Figure 2) nor in the aortic arch
(Supplementary Figure S2). Since plaque sizes were comparable between Western type diet
fed HDAC9 / ApoE / mice and wild type littermates, we could not address the question
whether HDAC9 deficiency in immune cells is sufficient for the atheroprotective effect.
For proteins important in adaptive immunity it is already known that they often only show
an effect on atherosclerosis when ApoE deficient mice are fed a chow diet and not a
Western type diet. For example, lymphocyte deficient Rag 1 knockout mice on an ApoE
deficient background showed a reduction in lesion size of almost 50% when fed a normal
chow diet, but no difference when fed a Western type diet.16 Similar experiments were
performed by Song et al. in LDLR deficient mice, analyzing the effect of Rag 1 deficiency
after different durations of Western type diet feeding.17 After 8 weeks on Western type
diet, Rag1 / LDLR / mice displayed a reduction of 54% in lesion size, while after 12 or
16 weeks, no reduction in lesion size was observed any longer.17 Histological analysis
demonstrated a lower complexity of lesions in Rag1 / LDLR / mice, which had mainly initial
foam cell lesions, indicating an involvement of lymphocytes in early atherogenesis.17
These findings from Rag 1 deficient mice are comparable to our data obtained in HDAC9
deficient animals. The biggest reduction of lesion size in HDAC9 deficient mice was seen at
18 weeks of age on chow diet. However, the difference was becoming smaller with time
(40% reduction in 18 week old vs. 26.5% reduction in 28 week old HDAC9 / ApoE / mice in
comparison to HDAC9+/+ApoE / mice), indicating a delay of atherogenesis by HDAC9
deficiency. This is supported by histological data from our previous study showing more
initial lesions in HDAC9 / ApoE / mice.8
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Figure 2. HDAC9 deficiency has no effect on atherosclerotic plaque size in Western type diet fed
mice. A, Representative images showing Oil Red O and hematoxylin stained cryosections from the
proximal aorta of HDAC9+/+ApoE / and HDAC9 / ApoE / mice fed a Western type diet (WD) or after
bone marrow transplantation (BMT). Scale bars: 250 μm. B, Quantification of the relative lesion area
(in relation to the area inside the external elastic lamina) demonstrates a significant reduction of
atherosclerosis in 18 and 28 week old HDAC9 / ApoE / mice on chow diet in comparison to their
wild type littermates,8 but no differences in Western type diet and bone marrow transplanted mice.
Results represent mean ± SEM; n = 7 13 for each genotype and time point; *P<0.05 vs. wild type
(Mann Whitney test).
To further validate this finding, we analyzed the amount of acellular cores in the
brachiocephalic artery of Western type diet mice. In contrast to 28 week old HDAC9
deficient mice on chow diet, which showed a significant reduction of acellular cores,8 no
difference in the acellular cores was observed in HDAC9 / ApoE / mice compared to wild
type littermates fed a Western type diet (Figure 3). These findings indicate an involvement
of HDAC9 in early atherogenesis. To answer the question if HDAC9 deficiency in immune
cells is sufficient for an atheroprotective effect, it is necessary to perform a bone marrow
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transplantation in ApoE deficient mice fed a normal chow diet or a Western type diet for a
shorter duration.
Figure 3. Western type diet fed HDAC9 / ApoE / mice have similar proportions of acellular cores in
atherosclerotic lesions as wild type littermates. A, Representative images of atherosclerotic plaques
in the brachiocephalic artery (BCA) of HDAC9 / ApoE / and HDAC9+/+ApoE / mice. Scale bars: 100 μm.
B, Quantification of acellular core per lesion area in the BCA of Western type diet fed HDAC9 / ApoE /
mice and their wild type littermates. n = 10 11 for each genotype.
HDAC9 deficiency affects monocyte populations in atherosclerotic mice
To study the distribution of different leukocyte subpopulations in HDAC9 deficient mice
during atherosclerosis, flow cytometry analysis of the spleen and the blood was performed
with specific immune cell markers. Blood leukocyte analysis did not reveal differences in
the leukocyte populations investigated (data not shown). HDAC9 / ApoE / mice on chow as
well as on Western type diet had a lower percentage of monocytes/macrophages
(CD11b+Ly6G ) in the spleen (Figure 4A and 4B). Moreover, when we compared the
classical, pro inflammatory Ly6C+ monocytes with non classical, resident Ly6C monocytes,
a shift toward the latter population was observed in HDAC9 deficient mice (Figure 4 and
Supplementary Figure S3), a finding in line with the observed reduction in lesion size. This
shift in Ly6C was only observed in HDAC9 / ApoE / mice but not in HDAC9 single knockout
mice (Supplementary Figure S3D), indicating that it represents a disease specific effect.
Differences were also detected in neutrophil percentages (CD11b+Ly6G+). However, these
were not consistent between 18 and 28 week old mice (Figure 4A and Supplementary
Figure S3A). HDAC9 deficient mice showed no differences in CD11c+ dendritic cells (data
not shown). Additionally, we also checked the expression of different cytokines and
chemokines which are important for macrophage and neutrophil function/migration in
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spleens from 28 week old mice. Expression of IFN , CXCL1, CXCL2 and CXCL5 was
comparable between HDAC9+/+ApoE / and HDAC9 / ApoE / mice (Supplementary Figure S4).
Figure 4. HDAC9 / ApoE / mice show reduced monocyte numbers and a shift to more Ly6C
negative, non classical, resident monocytes. Flow cytometric analysis of spleens from 18 week old
and Western type diet (WD) fed HDAC9+/+ApoE / and HDAC9 / ApoE / mice. A and B, Frequencies of
monocytes/macrophages (CD11b+Ly6G ) and neutrophils (CD11b+Ly6G+) (% of leukocytes). C and D,
Frequencies of Ly6C+ and Ly6C monocytes/macrophages (% of CD11b+Ly6G cells). n = 9 13 mice for
each genotype per group. *P<0.05; **P<0.01.
HDAC9 / ApoE / mice have a modest decrease in regulatory T cells
To investigate possible effects of HDAC9 deficiency on cells of the adaptive immune system,
we analyzed T cell populations by flow cytometry. We detected no differences in the
frequencies of T cells (CD3+), the T helper cell subpopulation (CD4+) or the cytotoxic T cell
subpopulation (CD8+) (Figure 5A, 5B, Supplementary Figure S5A and S5B). Surprisingly, we
measured a modest decrease in regulatory T cells (CD4+FoxP3+) in our HDAC9 / ApoE / mice
on chow and on Western type diet (Figure 5C, 5D and Supplementary Figure S5C), but not
in HDAC9 deficient mice without ApoE deficiency (Supplementary Figure S5D).
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Figure 5. HDAC9 / ApoE / mice show a modest decrease in regulatory T cells. Flow cytometric
analysis of spleens from 18 week old and Western type diet (WD) fed HDAC9+/+ApoE / and HDAC9 /
ApoE / mice. A and B, Frequencies of T cells (CD3+), T helper cells (CD3+CD4+) and cytotoxic T cells
(CD3+CD8+) (% of leukocytes). C and D, Frequencies of CD4+FoxP3+ regulatory T cells. n = 9 13 mice
for each genotype per group. *P<0.05.
These findings are in contrast to previously published data by Tao et al. showing that
HDAC9 deficient mice have a 50% increase in CD4+FoxP3+ T cells.15 Different wild type
controls may account for these contradictory observations. In our study, wild type
littermates were used. It is, however, not clear which controls the Tao et al. study used for
the analysis. Furthermore, only a number of 4 spleens were measured by Tao and
colleagues,15 while a minimum of 8 HDAC9 / ApoE / mice were used in the three different
groups in our study. Nevertheless, our data do not allow the conclusion that HDAC9 has no
influence on regulatory T cells, since the study by Tao et al. convincingly demonstrated that
HDACs, especially HDAC9, are important for the suppressive function of regulatory T cells.
Our modest decrease in regulatory T cells has probably no consequence on atherosclerosis.
Nevertheless, these cells could still be more suppressive than wild type regulatory T cells.
In addition to flow cytometry analysis, we assessed the ability of T cells to respond to
antigen stimulation using the production of pro inflammatory (IFN or IL 17) or anti
inflammatory (IL 10) cytokines as a read out system. Splenocytes from chow or Western
type diet fed HDAC9 / ApoE / mice showed similar patterns of cytokine secretion when
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stimulated in vitro with anti CD3 or anti CD3/CD28 antibodies (Figure 6). This data suggests
that despite the lack of HDAC9, antigen presenting cells can efficiently prime
T lymphocytes, that HDAC9 deficient T cells recognize and respond normally to antigen
encounter and that the effector T cell response is not disturbed in HDAC9 deficient mice.
Hence, other immune cells/pathways/mechanisms are responsible for the atheroprotective
effect seen in HDAC9 deficient mice.
Figure 6. HDAC9 deficiency has no influence on cytokine expression of splenocytes after T cell
stimulation. Splenocytes from 18 week old and Western type diet (WD) fed HDAC9+/+ApoE / and
HDAC9 / ApoE / mice were stimulated for 48 hours with anti CD3 or anti CD3/anti CD28 antibodies.
Levels of IFN (A and D), IL 17 (B and E) and IL 10 (C and F) were measured in the supernatants by
ELISA. All graphs represent mean ± SEM; n = 6 7 mice for each genotype per group.
Manuscript 2 HDAC9 in Immune Cells
59
HDAC9 / ApoE / mice show a reduction in CD4+ effector memory T cells
Besides regulatory T cells, we also checked the memory T cell populations by using the
CD44 and the CD62L (L selectin, homing receptor) markers. Interestingly, chow fed
HDAC9 / ApoE / mice showed a decrease in effector memory T cells within the CD4+
population (Figure 7 and Supplementary Figure S6A). This difference was only observed in
normal chow but not in Western type diet fed mice (Figure 7B) or in HDAC9 deficient mice
without ApoE deficiency (Supplementary Figure S6B). The decrease in effector memory
T cells could explain the reduced atherosclerosis in chow fed HDAC9 / ApoE / mice, due to
less activation and mobilization of T cells. Ammirati et al. demonstrated a correlation of
CD4+ effector memory T cells with the extent of atherosclerosis in animals and carotid
intima media thickness in humans.18 These data are well in line with our findings.
Figure 7. HDAC9 / ApoE / mice have less effector memory T cells. Flow cytometric analysis of
spleens from 18 week old and Western type diet (WD) fed HDAC9+/+ApoE / and HDAC9 / ApoE /
mice. A and B, Frequencies of naïve (CD44lowCD62Lhigh), central memory (CD44highCD62Lhigh) and
effector memory (CD44highCD62Llow) T cells within the CD4+ T cell population are shown. n = 9 13
mice for each genotype per group. **P<0.01.
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In conclusion, the present study highlights the importance of HDAC9 in early atherogenesis.
We could show that HDAC9 deficiency leads to a delay of atheroprogression. HDAC9
deficient mice on chow diet had less advanced lesions, but similar immune cell infiltration
into the plaques. We demonstrate a shift in monocyte/macrophage populations by flow
cytometry which is in line with the M2 anti inflammatory phenotype which Cao et al. could
recently show in peritoneal macrophages from HDAC9 / LDLR / mice.9 Besides macrophages,
also T cells seem to play an important role in HDAC9 deficient mice. Chow fed HDAC9 /
ApoE / mice show less effector memory T cells which fits to the reduced atherosclerosis in
these mice. Additional functional experiments are necessary to delineate the exact
mechanism and interaction of different cell types leading to the atheroprotective effect
mediated by HDAC9 deficiency. HDAC9 inhibition seems to be a promising therapeutic
strategy for the prevention of atherosclerosis.
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Supplementary Figures
Supplementary Figure S1. HDAC9 deficiency has no effect on immune cell infiltration in
atherosclerotic plaques. A, Quantification of CD45 positive stained area in atherosclerotic plaques of
the aortic valves showed no difference in leukocyte infiltration between 28 week old HDAC9 / ApoE /
mice and their wild type littermates. B, Quantification of CD3+ cells in the lamina (red arrow) and in
the plaque (blue arrow) of aortic valve sections showed no difference in T cell infiltration of 28 week
old mice. Scale bars: 100 μm; n = 8 13 for each genotype.
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Supplementary Figure S2. HDAC9 deficiency has no effect on atherosclerotic plaque size in
Western type diet fed or bone marrow transplanted mice on Western type diet. A, Representative
images showing dissected aortic arches and quantification of lesion sizes at the main branching
arteries and aortic curvature of Western type diet (WD) fed (A) and bone marrow transplanted mice
(BMT) (B). BCA brachiocephalic artery, CCA common carotid artery, SCA subclavian artery. All graphs
represent mean ± SEM; n = 7 11 mice for each genotype per group.
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Supplementary Figure S3. HDAC9 / ApoE / mice show reduced monocyte numbers and a shift to
more Ly6C negative, non classical, resident monocytes. Flow cytometric analysis of spleens from
28 week old HDAC9+/+ApoE / and HDAC9 / ApoE / mice and 20 week old HDAC9+/+ and HDAC9 /
mice. A and B, Frequencies of monocytes/macrophages (CD11b+Ly6G ) and neutrophils
(CD11b+Ly6G+) (% of leukocytes). C and D, Frequencies of Ly6C+ and Ly6C monocytes/macrophages
(% of CD11b+Ly6G cells). n = 5 13 mice for each genotype per group. *P<0.05; ***P<0.001.
Supplementary Figure S4. HDAC9 deficiency does not influence cytokine and chemokine
expression in the spleen. mRNA expression levels of IFN , CXCL1, CXCL2 and CXCL5 were measured
in the spleen of 28 week old HDAC9 / ApoE / and HDAC9+/+ApoE / mice. n = 8 13 mice for each
genotype. All graphs represent mean ± SEM.
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Supplementary Figure S5. HDAC9 / ApoE / mice show a modest decrease in regulatory T cells. Flow
cytometric analysis of spleens from 28 week old HDAC9+/+ApoE / and HDAC9 / ApoE / mice and
20 week old HDAC9+/+ and HDAC9 / mice. A and B, Frequencies of T cells (CD3+), T helper cells
(CD3+CD4+) and cytotoxic T cells (CD3+CD8+) (% of leukocytes). C and D, Frequencies of CD4+FoxP3+
regulatory T cells. n = 5 13 mice for each genotype per group. *P<0.05.
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Supplementary Figure S6. HDAC9 / ApoE / mice have less effector memory T cells. Flow cytometric
analysis of spleens from 28 week old HDAC9+/+ApoE / and HDAC9 / ApoE / mice and 20 week old
HDAC9+/+ and HDAC9 / mice. A and B, Frequencies of naïve (CD44lowCD62Lhigh), central memory
(CD44highCD62Lhigh) and effector memory (CD44highCD62Llow) T cells within the CD4+ T cell population.
n = 5 13 mice for each genotype per group. *P<0.05; **P<0.01.
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Abstract
The histone deacetylase 9 (HDAC9) gene region at chromosome 7p21.1 has been identified
as a major risk locus for atherosclerotic stroke and HDAC9 deficiency attenuated disease
progression in experimental models of atherosclerosis in mice. Since this makes HDAC9 a
potential drug target for stroke prevention, we wanted to evaluate the role of HDAC9 in
acute ischemic stroke.
HDAC9 mRNA levels significantly increased, almost two fold, in the ischemic brain 2 3 hours
after 60 min of middle cerebral artery occlusion followed by reperfusion.
HDAC9 deficient mice showed significantly larger infarct volumes and increased cell death
in peri ischemic areas 24 hours after stroke. The difference in infarct volume (+40%)
persisted until one week after ischemia and was accompanied by worse neurological
scores. Blood pressure, arterial blood gases, plasma electrolytes, vascular anatomy,
reperfusion, and brain edema formation were not different between HDAC9 deficient mice
and their wild type littermates.
Our results suggest a protective role of HDAC9 in acute ischemic stroke. Therapeutic
strategies to reduce atherogenesis and, hence, stroke incidence by inhibition of HDAC9
should therefore account for potential effects in acute ischemic stroke.
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Introduction
Genome wide association studies have identified the histone deacetylase 9 (HDAC9) gene
region (7p21.1) as the so far strongest risk locus for large vessel stroke.1,2 Common variants
at this locus were further found to be associated with coronary artery disease3 and
common carotid intima media thickness.4 We recently showed that the risk allele of
rs2107595, the lead single nucleotide polymorphism (SNP) in METASTROKE,2 is associated
with elevated HDAC9 mRNA expression in peripheral blood mononuclear cells.5 We and
others further demonstrated that HDAC9 deficiency is atheroprotective in mouse models
for atherosclerosis, making targeted inhibition of HDAC9 a potentially promising strategy
for prevention of atheroprogression and, hence, large vessel stroke.5,6
HDAC9 belongs to the family of histone deacetylases (HDACs) which removes acetyl groups
from lysine residues of histones and other non histone proteins, thus regulating gene
expression. The group of HDACs consists of 18 enzymes which can be classified according to
their molecular structure, cofactors, and subcellular localization. HDAC9 is a class IIa HDAC
and like all classical HDACs requires Zn2+ for its activity.7,8 Acetylation homeostasis plays an
important role in neuronal survival and in neurodegenerative disorders.9,10 HDAC inhibitors
have been shown to exhibit neuroprotective properties in several experimental stroke
models.11 13 Available pan HDAC inhibitors exhibit side effects and in vitro studies have
demonstrated potential neuroprotective effects of specific HDAC family members, including
HDAC9.14,15 Hence, there is growing interest in delineating the impact of individual HDACs
on neuronal survival. To characterize the role of HDAC9 in acute ischemic stroke in vivo, we
investigated the expression of HDAC9 in ischemic brain and subjected HDAC9 deficient mice
to transient middle cerebral artery occlusion (MCAo).
Materials and Methods
All animal studies were approved by the Ethical Review Board of the Government of Upper
Bavaria (protocol number 55.2 1 54 2532 187 13) and were performed in accordance with
national and institutional guidelines. Male C57BL/6 (18 to 22 g, Charles River, Sulzfeld,
Germany) and male, 6 week old HDAC9 deficient (HDAC9 / ) mice, initially generated by
E. Olson16, and their wild type littermates were used. All surgeries, quantifications, and
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analyses were done in a randomized manner and assessed by blinded investigators. The
results are reported according to the ARRIVE guidelines.
Transient Middle Cerebral Artery Occlusion Model
Transient middle cerebral artery occlusion (MCAo) was performed as previously
described.17,18 30 minutes prior to surgery, analgesia was provided with carprofen (4 mg/kg
s.c.). Anesthesia was induced using 4% isoflurane in a gas mixture of 30% oxygen and 70%
nitrous oxide and maintained with 1.5% isoflurane during surgery (15 20 minutes). A
feedback controlled heating pad was used to maintain body temperature at 37°C. Regional
cerebral blood flow (CBF) in the MCA territory was monitored continuously using a flexible
laser Doppler probe (PeriFlux System 5000, Perimed, Järfälla, Sweden) glued onto the
exposed left temporal bone. After ligation of the left common and external carotid arteries,
a silicone coated 7 0 monofilament (7019PK5Re, Doccol Corporation, Sharon, MA) was
introduced into the internal carotid artery and advanced further to occlude the MCA origin,
resulting in a CBF drop below 25% of baseline. After occlusion, the wounds were closed and
the animals were allowed to wake up. After 1 hour of MCA occlusion, mice were shortly
reanesthetized and the filament was withdrawn. In sham operated animals, the
monofilament was placed into the internal carotid artery without occlusion of the MCA.
Tissue Harvesting for Expression Analyses
Brains from C57BL/6 mice sacrificed 1h, 3h, 6h, or 24h after MCA occlusion were cut in
2 mm thick coronal slices (from Bregma to Bregma 2 mm) using a brain matrix (Zivic
Instruments, Pittsburgh, PA). The peri infarct region, infarct core, contralateral cortex, and
contralateral striatum were dissected (Figure 1A), incubated in RNAlater (QIAGEN, Hilden,
Germany) at 4°C overnight and then shock frozen on dry ice.
Real time PCR
Total RNA was isolated by RNeasy Lipid Tissue Mini Kit (QIAGEN, Hilden, Germany) and
cDNA was prepared from 1 μg RNA by the Omniscript RT Kit (QIAGEN, Hilden, Germany).
cDNA was diluted 1:20 and added to 200 nM gene specific primers and Brilliant II SYBR
Green QPCR Master Mix (Agilent Technologies, Santa Clara, CA). A total volume of 12 μl
(including 2 μl cDNA) was used. Real time PCR was performed on 384 well plates using the
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LightCycler 480 (Roche Diagnostics, Basel, Switzerland). Hypoxanthine guanine
phosphoribosyl transferase (HPRT) was used as a house keeping gene. Data were analyzed
based on the comparative threshold cycle method with the following formula: Relative
mRNA expression level = 2 Ct; Ct = Ct, target Ct, calibrator; Ct = Ct, HDAC9 Ct, HPRT.
The corresponding sample from the contralateral hemisphere was used as calibrator.
Following primers were designed for Real time PCR: 5’ CAATACCAGCAGCAGATCCA 3’ and
5’ GATTGGTCCCCCTGAAGC 3’ (for HDAC9); 5’ GATTAGCGATGATGAACCAGGTT 3’ and
5’ CCTCCCATCTCCTTCATGACA 3’ (for HPRT).
Infarct Volume Analysis
Infarct analysis was performed as previously described.18 Briefly, mice were euthanized
24 hours or 7 days after MCAo by cervical dislocation in deep isoflurane anesthesia and
brains were removed and shock frozen on dry ice. 12 coronal cryosections (10 μm) were
cut at an interval of 750 μm and then stained with cresyl violet. Infarct and hemisphere
areas were measured using a calibrated microscope and AxioVision Software (Zeiss, Jena,
Germany) and the infarct volume was calculated and corrected for brain edema using the
following formula:
Ainfarct, corr = Acontralateral hemisphere (Aipsilateral hemisphere Ainfarct);
Vinfarct = (Asection1+…+Asection12) * 750 μm.
Infarct volumes are expressed as percentages of the volume of the contralateral
hemisphere.
Assessment of the Vascular Anatomy in HDAC9 / mice
Mice were transcardially perfused with saline and 0.5 ml India ink in deep ketamine and
xylazine anesthesia. Brains were removed and the MCA territory of both hemispheres and
both posterior communicating arteries (PComA) were imaged. The diameter of the PComA
was scored as previously described (Score 0 3; 0 = absence of PComA, Score 3 = fully
developed PComA).18,19 The territory of the dorsal brain surface perfused by the MCA was
expressed as percentage of the hemisphere surface.
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Functional Outcome
A modified, five point Bederson test was performed as previously described.20 Briefly, the
scores were the following: 0 = normal neurological behavior; 1 = no circling, but clear
asymmetry in forepaw movement, when lifted by the tail; 2 = clear circling to contralateral
side, but normal posture at rest; 3 = lying on contralateral side at rest; 4 = no spontaneous
movement. Scores of 0.5, 1.5 and 2.5 were assigned when an intermediate phenotype was
observed. The tests were done in the evening throughout the observation period of 7 days
in parallel with measurements of body weight.
Physiological Monitoring before and after MCAo
Anesthesia was induced with 4% isoflurane and continued by an intraperitoneal injection of
fentanyl (0.05 mg/kg), midazolam (5 mg/kg), and medetomidine (0.5 mg/kg). After one
hour, anesthesia was maintained by injecting one third of the initial dose. Mice were oro
tracheally intubated and mechanically ventilated with a mixture of 70% air and 30% oxygen.
A catheter was placed in the left carotid artery for measuring mean arterial blood pressure
(MAP) continuously and electrolytes and blood gases at the beginning and the end of each
experiment. MCA occlusion was performed as described above.
Brain Edema
Brains from HDAC9 / mice and their wild type littermates were removed 24 hours after
MCAo. After separation of the hemispheres, the wet weight (W) of each hemisphere was
measured. Thereafter, the hemispheres were incubated at 110°C in an oven for 24 hours
and weighed again to determine the dry weight (D). Water content of each hemisphere was
determined with the following formula: ((W D)/W) * 100%.
TUNEL Staining
Cryosections were stained for cell death using the ApopTag Fluorescein In Situ Apoptosis
Detection Kit (Merck Millipore, Darmstadt, Germany). Two brain sections at Bregma
1.5 mm and 3 mm were selected per animal. Two regions of interest (ROI) were analyzed
on each section, one at the border of the MCA and ACA territory (ROI1) and one at the
piriform cortex (ROI2), a region specifically prone to selective post ischemic neuronal cell
death. A counting window of 0.075 mm2 was placed at the border of the TUNEL positive
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area and only the strong TUNEL positive cells were counted by using global threshold. The
quantification was done twice by two independent, blinded investigators. The averaged
means of both brain sections are shown.
Statistical Analysis
Statistical analysis was performed using SigmaPlot 12.5 (Systat Software Inc., San Jose, CA).
Pairwise comparisons were performed using the Mann Whitney rank sum test. Differences
were considered statistically significant at P<0.05. Data are presented as Box Whisker Plots
indicating the median and the 90th, 75th, 25th, and 10th percentiles or as mean ± SEM.
Results
HDAC9 expression increases after MCAo
HDAC9 mRNA expression was analyzed at different time points after MCAo in the peri
infarct region and the infarct core of C57BL/6 mice. The peri infarct region and the infarct
core were dissected as shown in Figure 1A. Besides 24h sham, two additional control
groups were used, 3h sham and naïve brains (without surgery). All control groups
demonstrated the same HDAC9 baseline expression (data not shown). HDAC9 mRNA
expression was significantly upregulated 1 hour and 3 hours after MCAo both in the peri
infarct region (Figure 1B) and in the infarct core (Figure 1C) (1.4 1.9 fold increase; P<0.05
versus 24h sham). HDAC9 expression decreased subsequently and reached 62% in the
infarct core at 24 hours after MCAo (P<0.05 versus 24h sham; Figure 1C).
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Figure 1. HDAC9 mRNA expression after MCAo in C57BL/6 mice. (A) Schematic drawing of how
coronal brain sections were dissected for RNA analysis. CLC: contralateral cortex, CLS: contralateral
striatum, IC: infarct core, PIR: peri infarct region. (B and C) HDAC9 mRNA expression increased in the
PIR and the IC within 1 3 hours after MCAo and decreased thereafter in comparison to the
corresponding contralateral brain regions. HDAC9 expression was normalized to HPRT expression.
Results represent mean ± SEM. *P<0.05.
HDAC9 deficiency increases infarct size 24 hours and 7 days after MCAo
To explore the effect of HDAC9 deficiency in acute ischemic stroke, HDAC9 deficient mice
were subjected to 1 hour of MCA occlusion and 23 hours of reperfusion. 24 hours after
MCAo, HDAC9 deficient mice showed significantly increased infarct areas at the level of the
coronal sections covering the MCA territory (Figure 2A), and their overall infarct volumes
were significantly larger as compared to wild type mice (28% ± 7% and 32% ± 3% of the
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contralateral hemisphere for HDAC9+/+ and HDAC9 / mice, respectively; mean ± SD; P<0.05;
Figure 2B). In an additional group with a 7 days observation period, increased infarct
volumes were still present in HDAC9 deficient mice (25% ± 8% and 35% ± 7% of the
contralateral hemisphere for HDAC9+/+ and HDAC9 / mice, respectively; mean ± SD; P<0.05;
Figure 2C and 2D); the difference between both groups was even more pronounced (+40%
as compared to +14% at day 1; P<0.05; Figure 2D).
Figure 2. Infarct volume analysis 24 hours and 7 days after MCAo. (A) Representative sections from
HDAC9+/+ and HDAC9 / mice and infarct area analysis showed larger areas of infarcted brain tissue at
the level of the MCA territory on coronal sections 24 hours after MCAo in HDAC9 deficient mice.
(B) Volumetric calculation of infarct sizes revealed significantly increased infarcts in HDAC9 deficient
mice 24 hours after MCAo. (C and D) The difference in infarct volume between HDAC9 deficient mice
and their wild type littermates was still present and even more pronounced 7 days after MCAo
(+40%). *P<0.05, **P<0.01.
To exclude that differences in vascular anatomy influence peri infarct perfusion and, hence,
infarct volume, we evaluated the vasculature in HDAC9 / and HDAC9+/+ mice by perfusion
with India ink. The MCA territory as well as the degree of collateralization between the
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anterior and the posterior vascular territories did not differ between HDAC9 deficient mice
and their wild type littermates (Figure 3).
Figure 3. Characterization of vascular anatomy of HDAC9 deficient mice and their wild type
littermates by transcardial India ink perfusion. Evaluation of the diameter of the posterior
communicating arteries (PComA) (A, arrows) and the brain surface covered by the MCA and its
branches (B, dashed line) showed no influence of HDAC9 deficiency on vascular anatomy.
HDAC9 deficiency leads to worse outcome during 7 days survival after MCAo
Long term functional outcome and mortality was analyzed during the 7 days observation
period after MCAo. Overall, 5 out of 13 HDAC9 / mice died in comparison to 4 out of 14
HDAC9+/+ mice (Figure 4A; P=0.51). HDAC9 / mice showed a trend toward increased body
weight loss and delayed body weight recovery during the 7 days (P=0.083 and P=0.069 for
day 6 and 7; Figure 4B). Motor function was examined prior to filament removal and daily
after MCAo (Supplementary Figure S1). No animal reached scores higher than 2.5. No
difference in the modified Bederson score was observed at the end of the 1 hour occlusion,
indicating that comparable areas of the brain were equally affected by MCAo (Figure 4C).
But 24 hours after MCAo, 8 out of 13 HDAC9 / mice showed severe deficits in comparison
to 5 out of 14 HDAC9+/+ mice (P=0.089, Figure 4C). 7 days after MCAo this difference was
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even more prominent: all HDAC9 / mice displayed persistent deficits while this was the case
in only 4 out of 10 HDAC9+/+ animals (P<0.01; Figure 4C).
Figure 4. Outcome 7 days after MCAo. (A) There was no difference in mortality during the 7 days
observation period. (B) HDAC9 deficient mice showed a trend toward worse body weight recovery
compared to their wild type littermates. (C) HDAC9 deficient mice showed worse functional outcome
24 hours and 7 days after MCAo. **P<0.01.
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HDAC9 deficiency has no effect on cerebral blood flow, animal physiology, and brain edema
formation
Monitoring of CBF during ischemia and reperfusion revealed no differences between
HDAC9 / and HDAC9+/+ mice, neither in the degree of CBF reduction during ischemia nor
during reperfusion (Figure 5A). Similarly, there were no differences in blood gases and
mean arterial pressure before and after ischemia between groups (Supplementary Table
S1). Analysis of brain edema 24 hours after MCAo showed similar brain water contents in
the non affected contralateral hemisphere (78.6% ± 0.3% for HDAC9+/+; 78.4% ± 0.4% for
HDAC9 / mice; mean ± SD) and the infarcted ipsilateral hemisphere (81.0% ± 0.8% for
HDAC9+/+; 81.0% ± 0.7% for HDAC9 / mice; mean ± SD), demonstrating that increased
infarct volumes in HDAC9 deficient mice were not associated with increased edema
formation (Figure 5B).
Figure 5. Post ischemic reperfusion and edema formation. (A) Cerebral blood flow during ischemia
and reperfusion was unaffected by HDAC9 deficiency. (B) Analysis of brain water content 24 hours
after MCAo revealed significant edema formation in the ipsilateral hemisphere. However, HDAC9
deficiency had no influence either on basal brain water content or on the formation of ischemic
brain edema. ***P<0.001.
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HDAC9 deficiency increased the number of TUNEL positive cells in the peri ischemic region
The differences in infarct volume and neurological score between HDAC9 / and wild type
mice were more pronounced 7 days post MCAo which could be a result of increased cell
death in the peri ischemic region. We analyzed this by quantifying TUNEL positive cells
24 hours after MCAo in two regions of interest, one at the border of the MCA and ACA
territory (ROI1) and one at the piriform cortex (ROI2), a region specifically prone to post
ischemic neuronal cell death. We observed significantly increased cell death in the piriform
cortex of HDAC9 deficient mice as compared to wild type littermates (ROI2 in Figure 6A and
6B).
Figure 6. Quantification of the number of cells with DNA damage 24 hours after MCAo by TUNEL
staining. (A) Representative image demonstrating the two regions of interest (ROI1 and ROI2) at the
peri ischemic region for quantification of TUNEL positive cells. (B) HDAC9 deficiency resulted in a
significantly higher number of TUNEL positive cells in the piriform cortex (ROI2). *P<0.05.
Discussion
The results of the current study suggest that HDAC9 may have a neuroprotective potential
after cerebral ischemia. This is demonstrated by larger infarct volumes 24 hours and 7 days
after MCAo, a trend toward worse body weight recovery and a worse neurological outcome
in HDAC9 deficient mice. Moreover, HDAC9 deficient mice showed increased numbers of
TUNEL positive cells in peri ischemic brain tissue. While the exact mechanisms mediating
the neuroprotective effect of HDAC9 remain unclear, we could exclude differences in
perfused MCAo territory or collateralization as underlying cause. Similarly, reperfusion,
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physiological parameters and brain edema were similar between HDAC9 deficient mice and
wild type littermates.
The observed increase in HDAC9 expression levels in ischemic brain within the first 3 hours
after MCAo is in agreement with similar results on ischemic core and penumbra lysates
obtained from rats sacrificed 24 hours after transient cerebral ischemia.21 Further evidence
for a potential role of HDAC9 in neuroprotection has been provided by in vitro data showing
that expression of the histone deacetylase related protein (HDRP), an isoform of HDAC9
lacking the histone deacetylase domain, is reduced in rat cerebellar granule neurons when
undergoing apoptosis induced by low potassium levels.14 By overexpressing HDRP, cell
death could be successfully inhibited.14 This is well in line with our results of increased
infarct volume, worse functional outcome and the elevated number of TUNEL positive cells
in HDAC9 deficient mice following cerebral ischemia. One possible interpretation for the
increased HDAC9 expression after experimental stroke is that HDAC9 is upregulated in
order to counteract cell death signaling.
Several reports describe beneficial effects of pan HDAC inhibitors in animal models of
neurodegeneration, such as Huntington disease,22 amyotrophic lateral sclerosis,23 spinal
muscular atrophy,24 dementia25 and stroke.11 13,26,27 Our current results are not necessarily
contradictory to these findings, since inhibiting more than one HDAC isoform might result
in pleiotropic effects obscuring the roles of individual HDACs. Moreover, a number of
HDAC associated processes, in particular those dependent on type II HDACs such as HDAC9,
have been shown to not require deacetylase activity. It is therefore conceivable that pan
HDAC inhibitors only marginally interfere with HDAC9 functions.
We and others recently showed an attenuation of atheroprogression in HDAC9 / mice.5,6
These results are in line with recent genome wide association studies which identified an
association of the HDAC9 gene region with large vessel stroke1,2 and coronary artery
disease,3 indicating a specific involvement of HDAC9 in atherosclerosis. HDAC9 may
therefore represent a promising pharmacological target for the treatment of this disease.
Since, however, patients with atherosclerosis are also often affected by ischemic stroke and
our results suggest a protective function of HDAC9 after cerebral ischemia, specific caution
is required when developing HDAC9 inhibitors for the treatment of atherosclerosis. A
possible approach could be to develop HDAC9 inhibitors which do not cross the blood brain
barrier and might thus have no or minimal effects on stroke outcome.
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In summary, our current results demonstrate that HDAC9 deficiency increases cell death
and worsens long term outcome following transient cerebral ischemia. This suggests a
robust and long lasting protective role of HDAC9 in the ischemic brain which needs to be
carefully considered when exploiting the anti atherogenic potential of HDAC9 inhibitors.
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Supplementary Information
Supplementary Figure S1
Figure S1. Daily neurological examinations resulted in a trend toward worse motor function in
HDAC9 deficient mice which reached significance 7 days after MCAo. **P<0.01.
Supplementary Table S1. Physiological values
before ischemia after ischemia
HDAC9
+/+
HDAC9
/ P value HDAC9
+/+
HDAC9
/ P value
MAP (mmHg) 124 ± 21 123 ± 16 n.s. 86 ± 21 90 ± 25 n.s.
pH 7.35 ± 0.06 7.36 ± 0.08 n.s. 7.29 ± 0.09 7.33 ± 0.02 n.s.
pCO
2
(mmHg) 39.7 ± 5.9 36.4 ± 2.8 n.s. 35.7 ± 2.5 37.5 ± 3.3 n.s.
pO
2
(mmHg) 120.7 ± 29.4 166.6 ± 21.7 < 0.01 131.3 ± 15.6 140.6 ± 14.7 n.s.
Na
+
(mmol/L) 140 ± 5 139 ± 5 n.s. 144 ± 4 144 ± 5 n.s.
K
+
(mmol/L) 4.88 ± 0.75 4.71 ± 0.84 n.s. 6.14 ± 1.90 5.95 ± 1.34 n.s.
Ca
++
(mmol/L) 1.12 ± 0.08 1.11 ± 0.07 n.s. 1.10 ± 0.18 1.14 ± 0.08 n.s.
HCT (%) 43 ± 5 43 ± 6 n.s. 51 ± 8 49 ± 7 n.s.
O
2
Sat (%) 97.6 ± 1.3 98.3 ± 1.3 n.s. 97.3 ± 2.5 97.7 ± 1.4 n.s.
mean ± SD, HDAC9
+/+
: n = 7 8, HDAC9
/
: n = 5 6, MAP: mean arterial pressure, Mann Whitney U
test, n.s.: not significant
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7 Discussion
The HDAC9 gene locus at chromosome 7p21.1 was recently identified as a risk locus for LVS
(Bellenguez et al., 2012; Traylor et al., 2012). The 7p21.1 locus shows only association with
LVS and not with the other two subtypes of ischemic stroke, cardioembolism or small vessel
disease. Additionally, this locus has also been associated with CAD and carotid intima
media thickness (Deloukas et al., 2013; Markus et al., 2013). HDAC inhibitors have already
demonstrated neuroprotective and anti inflammatory properties in several studies, making
HDAC9 an interesting target for stroke research. In the first part of this thesis the role of
HDAC9 deficiency was analyzed in a mouse model for atherosclerosis, which is the
underlying pathology of LVS and CAD. In the second part, HDAC9 deficient mice were
subjected to acute ischemic stroke and the functional as well as the histological outcome
was investigated.
HDAC9 deficiency is atheroprotective
In the first part of this thesis, we got further insights into the biological role of HDAC9 in
atherosclerosis. Our results suggest that HDAC9 inhibition is a promising therapeutic
strategy for prevention of atherosclerosis.
The hypothesis of an atheroprotective effect of HDAC9 deficiency was based on data from
my colleague Caroline Prell Schicker, who demonstrated that HDAC9 mRNA levels were
significantly increased in homozygous and heterozygous risk allele carriers of the
METASTROKE lead SNP rs2107595 (Azghandi et al., 2015). The two other neighboring genes
in the 7p21.1 region, TWIST1 and FERD3L, did not show any correlations of mRNA levels
with allele carrier status, making HDAC9 the most promising candidate gene within this
region. The increased HDAC9 mRNA levels in risk allele carriers led to the hypothesis that
HDAC9 deficiency/inhibition should be protective. We confirmed this hypothesis,
demonstrating protective effects of HDAC9 deficiency in a mouse atherosclerosis model,
ApoE / mice, which were presented in manuscripts 1 and 2.
HDAC9 / ApoE / mice had significantly reduced atherosclerosis throughout the aorta at two
time points (Azghandi et al., 2015). However, a third group of mice, which was fed a high
cholesterol Western type diet, showed no difference in plaque size between
HDAC9 / ApoE / and HDAC9+/+ApoE / mice. These data demonstrate the importance to study
different diets and time points in experimental atherosclerosis models. Our Western type
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diet data help to understand which stage of atherosclerosis is affected by HDAC9
deficiency. We conclude that HDAC9 is mainly important in early atherogenesis. This
conclusion is based on the observation that (1) HDAC9 deficient mice on chow diet had
more initial lesions than wild type littermates, (2) the degree of plaque size reduction got
smaller with increased age (18 week old vs 28 week old mice) and (3) in Western type diet
fed mice with more advanced plaques differences in plaque size between HDAC9+/+ApoE /
and HDAC9 / ApoE / mice could no longer be detected. The atheroprotective effect of
HDAC9 deficiency was also demonstrated by another group in a second atherosclerosis
model, LDLR / mice (Cao et al., 2014), showing that the phenotype is very robust,
reproducible and independent of the atherosclerosis model. LDLR / mice have to be fed a
high cholesterol diet to develop atherosclerotic lesions in contrast to ApoE deficient mice
which develop atherosclerotic lesions spontaneously on a chow diet. Another difference
between the two mouse models is that for bone marrow transplantation into ApoE
deficient mice, the donor bone marrow has to be ApoE deficient in contrast to donors for
LDLR / mice where the bone marrow can have an LDLR wild type genotype (Linton et al.,
1995; Herijgers et al., 1997). This shows that these two models differ in the mechanism
inducing atherosclerosis, but the reproducible effect of HDAC9 deficiency in both models
makes HDAC9 inhibition a very promising strategy for humans.
HDAC9 deficiency influences monocyte/macrophage dynamics
HDACs are known to play an important role in inflammation and immunity (Shakespear et
al., 2011). Several studies have shown an involvement of HDACs in innate immunity.
Classical HDACs influence macrophage and dendritic cell function by targeting Toll like
receptor and IFN signaling (Shakespear et al., 2011). Recent studies showed that HDACs
such as HDAC3 and HDAC7 regulate inflammatory gene expression in macrophages (Chen
et al., 2012; Shakespear et al., 2013). Macrophages contribute to the different stages of
atherosclerosis by inducing inflammatory processes, forming foam cells and eventually the
necrotic core of an advanced plaque (Moore et al., 2013). Macrophages can be grouped in
M1 and M2 macrophages. Classically activated macrophages of the M1 type are pro
inflammatory and regarded as pro atherogenic while M2 macrophages are characterized by
anti inflammatory cytokine profiles and are associated with wound healing and
atherosclerosis regression (Moore et al., 2013).
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Cao et al. observed in LDLR / mice that HDAC9 deficient macrophages exhibited an
upregulated expression of cholesterol efflux genes such as ABCA1 and ABCG1, expressed
less pro inflammatory cytokines after LPS stimulation, and demonstrated an M2 like
phenotype in vitro (Cao et al., 2014). In ApoE deficient mice, we could show that HDAC9
deficiency leads to a Ly6C shift in monocytes/macrophages, meaning HDAC9 / ApoE / mice
had less inflammatory Ly6C+ and more resident, patrolling Ly6C monocytes (see
manuscript 2). It is known that hypercholesterolemic ApoE / mice have an expansion of
circulating monocytes, mainly due to an increase in Ly6C+ monocytes (Swirski et al., 2007).
Monocytosis in atherosclerotic mice results from increased survival, continued proliferation
and lower conversion rates from Ly6C+ to Ly6C monocytes (Swirski et al., 2007). Besides a
Ly6C shift to more Ly6C monocytes, we observed a reduced monocyte frequency in
HDAC9 / ApoE / mice in comparison to HDAC9+/+ApoE / mice.
Additional analysis of survival, proliferation and conversion rates of HDAC9 deficient Ly6C+
monocytes could give further insights into the involvement of monocytes in the
atheroprotective mechanism of HDAC9 deficiency. In our group, we are currently assessing
migration and cytokine expression of macrophages exposed to different pro inflammatory
stimuli to understand how monocytes/macrophages contribute to the observed phenotype
in HDAC9 / ApoE / mice.
HDAC9 deficiency affects memory T cell distribution
Besides monocytes/macrophages, we also analyzed T cell distribution in HDAC9 / ApoE /
mice on chow and on Western type diet using flow cytometry. We did not detect any
differences in T cell frequency or in the relative amount of CD4+ and CD8+ subpopulations.
HDAC9 has already been known as an important regulator of the function of regulatory
T cells (Tao et al., 2007). Tao et al. showed an increase in Tregs by 50% in HDAC9 deficient
mice. In contrast, we did not see any differences in frequency of Tregs in HDAC9 deficient
mice without ApoE deficiency (see manuscript 2). This is probably due to different wild type
controls that were used in the studies. We always used wild type littermates as controls in
order to exclude background differences. It is not clear whether Tao et al. used normal
C57BL/6 mice or littermates as controls. Furthermore, only a low number of spleens were
analyzed in their study (n = 4). In our HDAC9 / ApoE / mice, we measured a modest
decrease in Treg frequencies, in chow and Western type diet fed mice. We do not believe,
Discussion
88
however, that this decrease has a physiological importance or that it means that HDAC9 is
not important for Tregs. Tao et al. could show that Tregs have higher HDAC9 mRNA levels
than effector T cells, that Treg stimulation induces nuclear export of HDAC9, and HDAC9
deficient Tregs were three to fourfold more suppressive than controls and had increased
FoxP3 acetylation (Tao et al., 2007). Therefore additional experiments are necessary to
delineate the function of Tregs in HDAC9 / ApoE / mice.
Moreover, our FACS data revealed a very interesting difference in another T cell population,
the effector memory T cells. HDAC9 / ApoE / mice on chow diet had significant less effector
memory T cells within the CD4+ population (see manuscript 2). The decreased effector
memory T cells indicate decreased activation and mobilization of T cells in HDAC9 deficient
mice, which fits with the reduced atherosclerotic plaque size in chow fed HDAC9 / ApoE /
mice. A recent study demonstrated a correlation of CD4+ effector memory T cells with the
extent of atherosclerosis in animals and carotid intima media thickness as well as coronary
artery disease in humans (Ammirati et al., 2012), suggesting that effector memory T cells
may represent an important immune cell population in atherogenesis.
Our data from monocytes/macrophages and T cells in HDAC9 / ApoE / mice show that both
innate and adaptive immunity might play an important role in the atheroprotective effect
mediated by HDAC9 deficiency.
HDAC9 deficiency worsens ischemic stroke outcome
All identified loci in the METASTROKE data set showed only association with one ischemic
stroke subtype, emphasizing the importance of distinguishing the different stroke subtypes
from each other (Traylor et al., 2012). The HDAC9 gene region showed exclusive association
with large vessel stroke, where the underlying pathology is atherosclerosis. This is why we
analyzed the effects of HDAC9 deficiency in a mouse atherosclerosis model. However,
several studies have already demonstrated beneficial effects of HDAC inhibitors in models
for stroke and neurodegenerative diseases (Kazantsev and Thompson, 2008; Shein and
Shohami, 2011). In the second part of this thesis, the role of HDAC9 in ischemic stroke
outcome was analyzed by using the MCAo model in HDAC9 deficient mice (see
manuscript 3). Surprisingly, HDAC9 deficient mice demonstrated larger infarct volumes 24
hours and 7 days after ischemic stroke. The increase in infarct volume was also reflected in
worse neurological scores. We checked blood pressure, blood gases and vascular anatomy
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(MCA territory as well as the degree of collateralization between the anterior and posterior
cerebral circulation) and did not detect any differences. Also brain edema formation and
reperfusion were not affected by HDAC9 deficiency. The detailed mechanism of increased
infarct volume and worse functional outcome is still unclear but we hypothesize that the
worse outcome is based on increased cell death due to our finding of elevated numbers of
TUNEL positive cells in peri ischemic areas of HDAC9 deficient mice. Moreover, another
study already demonstrated that an HDAC9 isoform, lacking the deacetylase domain, is
important for neuronal survival in vitro (Morrison et al., 2006). We also detected increased
levels of HDAC9 in peri infarct regions of wild type mice in the first hours after stroke,
indicating that cells may upregulate HDAC9 to counteract cell death signaling.
Since the promising atheroprotective results of HDAC9 deficiency make HDAC9 a potential
drug target to prevent atherosclerosis, development of HDAC9 inhibitors should consider
negative effects of these inhibitors in the brain. The potential patient target group for
HDAC9 inhibitors are people at risk for atherosclerosis who are also at risk for stroke.
Therefore it is important to understand in more detail the effect of such inhibitors on the
brain.
HDAC9 belongs to the class IIa HDACs for which the exact mechanism of repression has not
been fully discovered. Class IIa HDACs have a minimal catalytic activity and therefore
regulate transcription by interacting with other multiprotein complexes containing
class I HDACs, like HDAC3 (Fischle et al., 2002; Lahm et al., 2007). HDAC9 has several
isoforms including some without a deacetylase domain, demonstrating that catalytic
activity is not necessary for its function (Petrie et al., 2003). This could also explain why pan
HDAC inhibitors are neuroprotective while HDAC9 deficiency worsens neuronal cell death.
The catalytic activity of HDAC9 may not be important for its function in neuronal survival.
Therefore it is of utmost importance to understand the molecular mechanism underlying
the atheroprotective effect of HDAC9 deficiency in comparison with the neuroprotective
effect of HDAC9.
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Outlook
Since the results of this thesis make HDAC9 a potential drug target for atherosclerosis and
stroke prevention, the exact mechanisms underlying its effects have to be discovered. On
the one hand, responsible cell types for the atheroprotective effect of HDAC9 deficiency
have to be identified. The data reported in this thesis suggest that a combined effect of
several cell types is responsible for the reduced atherosclerosis phenotype in
HDAC9 / ApoE / mice. In our group several in vitro approaches are under investigation to
test different cell types, including macrophages, T cells but also smooth muscle and
endothelial cells. My colleague Yaw Asare has already obtained promising results, showing
that also smooth muscle cells and endothelial cells express less atherogenic molecules after
HDAC9 knockdown in combination with inflammatory stimulation. Besides the cell type, the
underlying pathway by which inhibition of HDAC9 influences inflammatory signaling has to
be elucidated. These experiments can be done in animal models but the results have to be
transferred to humans. Immune cells seem like a promising target considering the HDAC9
expression data in human PBMCs and my own data showing that monocytes and effector
memory T cells are candidate cells for HDAC9 inhibition. My colleague Caroline Prell
Schicker has already investigated FoxP3 and HDAC9 expression in Tregs isolated from risk
allele carriers of the rs2107595 lead SNP. However, she did not detect any differences in
expression. Based on the results of this thesis, we now plan to investigate other immune
cell types in risk allele carriers of rs2107595, such as monocytes and
CD4+ effector T cells. Another interesting question, which our group is addressing, is how
variants at this locus regulate HDAC9 expression. For another locus, the 1p13 locus, which
was found to be associated with myocardial infarction and plasma low density lipoprotein
cholesterol by GWAS, Musunuru et al. could show how noncoding variants can lead to a
clinical phenotype. The risk allele creates a new transcription binding site for
C/EBP transcription factors which leads to increased liver specific expression of the
transporter protein Sortilin (Musunuru et al., 2010). Our lead SNP rs2107595 is located in a
DNase I hypersensitity cluster and histone modification hotspot, indicating a regulatory
function (Azghandi et al., 2015). Indeed, the TRANSFAC database (Wingender et al., 2000)
predicts that the risk allele of rs2107595 disrupts a binding site for the E2F3 transcription
factor. This is a new project under investigation in our group.
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Conclusion
In summary, the results of this thesis give insights into the beneficial effect of HDAC9
deficiency in atherosclerosis. We provide further evidence that HDAC9 is the disease
relevant gene at the 7p21.1 locus associated with LVS and CAD, demonstrating how GWAS
can identify new target genes for complex diseases. We could show that HDAC9 deficiency
reduces early atherogenesis and propose an immune cell mediated mechanism by both
innate and adaptive immunity. HDAC9 deficiency has an effect on monocyte/macrophage
dynamics as well as on effector memory T cells. Our results suggest that pharmacological
inhibition of HDAC9 might be a promising therapeutic strategy for the prevention of
atherosclerosis and LVS. Additional experiments are necessary to discover the mechanism
by which variants at this locus regulate HDAC9 expression and how HDAC9 influences
inflammatory signaling in the identified immune cell types.
In addition to atherosclerosis, we also investigated ischemic stroke outcome in HDAC9
deficient mice. HDAC9 deficiency seems to aggravate infarct volume and neurological
outcome after acute ischemic stroke, indicating that HDAC9 has a neuroprotective function
in the brain. Therefore the data presented in this thesis strongly suggest that potential
negative effects of HDAC9 inhibitors on the brain have to be considered in the development
of respective compounds.
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